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Background: PCSK9 (proprotein convertase subtilisin/kexin type 9), is a protein, mainly 
synthesized and secreted by the liver, which binds to specific target proteins and escorts 
them towards lysosomes for degradation. The best defined activity of PCSK9 is its ability 
to modulate the hepatic uptake of LDL cholesterol (LDL-C), by enhancing the intracellular 
degradation of the LDL receptor (LDLR). In humans, several mutations in PCSK9 gene were 
described, both “gain-of-function” mutations associated to hypercholesterolemia and 
“loss of function” mutations linked to low LDL-C levels [1]. These findings suggest PCSK9 
inhibitors as a promising class of drugs for the treatment of patients with severe 
hypercholesterolemia or at very high cardiovascular risk. However, some gaps regarding 
the potential role of PCSK9 in targeting the LDLR in organs other than the liver are still 
open. Indeed, the LDLR is abundantly expressed in pancreatic β-cells, where it plays a key 
role in the uptake of plasma LDL particles [2]. Therefore, further investigations are 
needed to better clarify the physiological role of PCSK9, also in light of its pharmacological 
targeting. 
Methods: WT, PCSK9 KO, LDLR KO, PCSK9/LDLR DKO, albumin (Alb)Cre+/PCSK9LoxP/LoxP 
(liver selective PCSK9 KO mice) and AlbCre-/PCSK9LoxP/LoxP mice were fed a HFD (High Fat 
Diet – 45% Kcal fat) or SFD (Standard Fat Diet – 10% Kcal fat) for 12 or 20 weeks. GTT, ITT, 
insulin and C-peptide plasma levels, pancreas morphology and cholesterol accumulation 
in pancreatic islets were studied in the different animal models.  
Results: Glucose clearance was significantly impaired in PCSK9 KO mice fed a SFD or a 
HFD for 20 weeks compared to WT animals, with both diet. On the contrary, insulin 
sensitivity was not affected as both animals showed a similar decrease in plasma glucose 
levels following insulin injection (ITT). Plasma insulin and C-peptide levels were reduced in 
PCSK9 KO mice compared to WT and accordingly fasting and refeeding experiments 
showed increased plasma glucose but reduced insulin levels in PCSK9 KO compared to 
controls. A detailed analysis of pancreas morphology of PCSK9 KO mice vs WT littermates 
revealed larger islets with increased accumulation of cholesteryl esters, paralleled by 
increased insulin intracellular levels. This phenotype was completely reverted in 
PCSK9/LDLR DKO mice implying the LDLR as the PCSK9 target responsible for the 
phenotype observed. Further studies in AlbCre+/PCSK9LoxP/LoxP, which lack detectable 
circulating PCSK9, also showed a complete recovery of the phenotype, thus indicating 
that circulating, liver-derived PCSK9 does not impact β-cells function and insulin 
secretion.  
Conclusion:The PCSK9/LDLR axis affects β-cells function and control insulin secretion. Our 
data indicate that this effect is independent of circulating PCSK9, and is probably related 
to local effects of PCSK9 suggesting the possibility that anti-PCSK9 antibodies or liver 
specific therapies, such as siRNAs, might have a limited impact on LDLR expression in 
pancreas and β-cells dysfunction.  
 
Ruolo di PCSK9 (proproteina convertasi subtilisina/kexina di tipo 9)  
nel metabolismo glucidico  
 
Obiettivo: PCSK9, enzima della classe delle proteasi, viene secreto nel circolo sanguigno 
dove regola i livelli plasmatici di lipoproteine a bassa densità (LDL), favorendo la 
degradazione dei recettori per le LDL (LDLR) principalmente a livello epatico. Numerose 
mutazioni nel gene codificante per PCSK9 sono state descritte, associate sia ad 
ipercolesterolemia che a bassi livelli di LDL colesterolo (LDL-C) e ridotto rischio 
cardiovascolare [3]. Queste osservazioni hanno favorito il rapido sviluppo di diverse 
strategie volte all’inibizione farmacologica di PCSK9, soprattutto nel trattamento di 
soggetti con ipercolesterolemia familiare (FH). Tuttavia, la presenza del LDLR e di altri 
recettori target di PCSK9 in numerosi tessuti extra-epatici [4], potrebbe significare un 
ruolo critico della proteina in diverse patologie metaboliche. In particolare, lo scopo del 
seguente progetto è stato quello di valutare l’impatto di PCSK9 nel pancreas e nel 
metabolismo glucidico, avvalendosi di differenti modelli animali.      
Materiali e metodi: Topi maschi WT, PCSK9 KO, LDLR KO, PCSK9/LDLR DKO, 
albumin(Alb)Cre+/PCSK9LoxP/LoxP (topi PCSK9 KO condizionali) e AlbCre-/PCSK9LoxP/LoxP , 
sono stati alimentati per 12 o 20 settimane con una dieta standard (SFD) o con una dieta 
ricca in lipidi (HFD), in grado di indurre obesità e disfunzione metabolica. GTT, ITT, livelli 
plasmatici di insulina e C-peptide, espressione del LDLR, morfologia e contenuto lipidico 
delle isole pancreatiche sono stati valutati nei differenti gruppi sperimentali.  
Risultati: Test di tolleranza al glucosio (GTT) e test di tolleranza all’insulina (ITT) hanno 
evidenziato una marcata intolleranza al glucosio nei topi PCSK9 KO rispetto ai topi WT, 
con entrambe le diete, non associata allo sviluppo di insulino-resistenza. I livelli plasmatici 
di insulina e C-peptide sono risultati significativamente ridotti nei topi PCSK9 KO, in 
associazione ad un accumulo di insulina nel pancreas, suggerendo un’alterazione nel 
processo di secrezione dell’ormone a livello delle cellule β pancreatiche. Queste 
osservazioni sono state confermate dall’analisi morfologica di isole di topi PCSK9 KO e 
WT. L’assenza di PCSK9 si associa inoltre ad una maggiore espressione del LDLR a livello 
pancreatico, con conseguente accumulo di lipidi. Al contrario, topi PCSK9/LDLR DKO non 
presentano alterazioni metaboliche rispetto ai controlli LDLR KO, suggerendo il ruolo 
chiave del LDLR alla base del fenotipo osservato nei topi PCSK9 KO. Anche studi in topi 
AlbCre+/PCSK9LoxP/LoxP, che mancano di PCSK9 solo a livello epatico, non mostrano 
differenze rispetto ai controlli.  
Conclusioni: PCSK9 modula l’espressione del LDLR a livello pancreatico, svolgendo un 
ruolo cruciale nella funzionalità delle cellule β e nel processo di secrezione di insulina 
dalle stesse. I dati riportati indicano inoltre che l’effetto osservato a livello del pancreas è 
indipendente da PCSK9 circolante, principalmente prodotto a livello epatico, ma 
probabilmente associato alla proteina prodotta localmente. Queste osservazioni 
forniscono informazioni chiave riguardo il ruolo di PCSK9 nel metabolismo glucidico, utili 
soprattutto in ottica della sicurezza degli inibitori farmacologici di PCSK9.  
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Abbreviations 
2h PG       2h Plasma Glucose 
ABCA1      ATP-Binding Cassette Transporter A1 
ABCG1      ATP-Binding Cassette Transporter G1 
ACAT1      Acetyl-CoA Acetyltransferase 
AD       Alzheimer’s Disease  
ADH       Autosomal Dominant Hypercholesterolemia 
ApoB       Apolipoprotein B  
ApoER2      Apolipoprotein E Receptor 2 
ASOs       Antisense Oligonucleotides  
AUC       Area Under the Curve 
Aβ       Amyloid Β-Peptide  
BACE1      Β-site Amyloid Precursor Protein (APP)- 
      Cleaving Enzyme 1 
CD36      Cluster Of Differentiation 36 
CGN       Cerebellar Granule Neurons 
CRE       Cyclic AMP Response Element  
DM       Diabetes Mellitus  
DPP-4      Dipeptidyl Peptidase 4 
DRP1      Dynamin-Related Protein 1 
ECs       Endothelium Cells 
EGF-A       Epidermal Growth Factor-A  
eIF2a       Eukaryotic Initiation Factor 2a 
ENaC       Epithelial Na+ Channel 
ER       Endoplasmic Reticulum 
FFA       Free Fatty Acid 
FH       Familial Hypercholesterolemia 
FPG       Fasting Plasma Glucose 
G6P      Glucose 6-Phosphate 
GDM      Gestational Diabetes  
GIP       Glucose-Dependent Insulinotropic Peptide 
GK       Glucokinase 
GLP-1      Glucagon-Like Peptide 1 
GLP-1R      GLP-1 Receptor 
GLUT2      Glucose Transporter 2  
GLUT4      Glucose Transporter 4  
GOF       Gain-Of-Function 
GSIS       Glucose Stimulated Insulin Secretion 
GTT       Glucose Tolerance Test 
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GWAS       Genome-Wide Association Studies 
HbA1c      Hemoglobin A1c 
HFD       High Fat Diet  
HLA       Human Leukocyte Antigen 
HMGCoA-R      3-Hydroxy-3-Methylglutaryl-Coenzyme A  
      Reductase 
HNF1α      Hepatocyte Nuclear Factor 1α  
ICA512     Islet Cell Autoantigen 512 
IL-6      Interlukin-6 
IMT       Intima Media Thickness 
IPGTT       Intraperitoneal Glucose Tolerance Test 
IR       Insulin Receptor 
IRS       Insulin Receptor Substrate 
ITT       Insulin Tolerance Test 
KATP channel      ATP-Sensitive Potassium channel 
LDL      Low Density Lipoprotein 
LDL-C       LDL Cholesterol 
LDLR       LDL Receptor 
LOF       Loss-Of-Function  
LXR       Liver X Receptor 
mAbs       Monoclonal Antibodies  
MRI       Magnetic Resonance for Imaging  
MTNR       Melatonin Receptor 
NAFPD      Nonalcoholic Fatty Pancreas Disease 
NARC-1     Neural Apoptosis-Regulated Convertase 1 
nNOS       Neuronal NO Synthase   
OA       Oleanolic Acid  
OGTT       Oral Glucose Tolerance Test 
oxLDL       Oxidized LDL  
PC      Proprotein Convertase 
PCR       Polimerase Chain Reaction  
PCSK9      Proprotein convertase subtilisin/kexin type 9 
PDX-1      Duodenal Homeobox-1  
PERK       Pancreatic ER Kinase 
 PP1      Protein Phosphatase 1  
PPAR       Peroxisome Proliferator-Activated Receptor 
RIPE3b      Rat Insulin Promoter Element 3b  
ROS       Reactive Oxygen Species 
 RTK       Receptor Tyrosine Kinase 
RT-PCR      Real Time Quantitative Polymerase Chain  
      Reaction 
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SCAT       Subcutaneous Adipose Tissue  
SFD       Standard Fat Diet  
SH2      Src-Homology 2 
siRNA       Small Interfering Rna  
SMCs       Smooth Muscle Cells  
SNPs       Single Nucleotide Polymorphisms 
SRE      Sterol-Responsive Elements  
SREBP1c      Sterol Regulatory Element-Binding Protein 1c 
T1DM       Type 1 Diabetes Mellitus  
T1R2      Taste Receptor Type 1  
T2DM       Type 2 Diabetes Mellitus  
TCA Cycle     Tricarboxylic Acid Cycle 
TG       Triglycerides  
TNF-α       Tumor Necrosis Factor-Α  
UCP-2      Uncoupling Protein-2  
UPR       Unfolded Protein Response 
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1. Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic disorders characterized by a chronic 
hyperglycemic condition due to dysfunction in insulin secretion, insulin action or both. 
The chronic hyperglycemia causes long-term damage, dysfunction and failure of different 
tissues and organs, such as the eyes, heart, kidneys, nerves and blood vessels. The 
pathogenic processes involved in the onset and development of diabetes include both 
autoimmune disorders, associated with the destruction of the pancreatic β-cells, and 
deficient action of insulin on target tissues, resulting in abnormalities in carbohydrate, fat 
and protein metabolism [5].  
Particularly, there are three main types of diabetes mellitus: 
 Type 1 DM: is a consequence of the pancreatic failure in producing enough insulin, 
due to autoimmune β-cell destruction. This form was previously known as "insulin-
dependent diabetes mellitus" (IDDM) or "juvenile diabetes". 
 Type 2 DM: begins with insulin resistance, a condition in which cells respond to insulin 
less than expected, leading  to a progressive loss of β -cell insulin secretion. This form 
was referred to as "non insulin-dependent diabetes mellitus" (NIDDM) or "adult-onset 
diabetes". 
 Gestational diabetes (GDM): occurs when pregnant women, without a previous 
history of diabetes, develop hyperglycemia. It is usually diagnosed in the second or 
third trimester of pregnancy. 
 
The prevalence of diabetes is increasing rapidly worldwide and it is estimated that 
currently 415 million adults (8.4%) have diabetes. In 2015 the International Diabetes 
Federation predicted that one-third of adults are expected to have diabetes in 2050 in the 
USA and that there will be 71.1 million adults living with diabetes in Europe [6]. 
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1.1 Physiology of glucose homeostasis 
Glucose, a fundamental source of cellular energy, represents an important precursor for 
the synthesis of several biomolecules and plays an important role in cell signalling. Plasma 
glucose concentration depends on the rate of glucose entering the circulation balanced 
by the rate of glucose removed from the circulation. A considerable fraction of plasma 
glucose derives from the intestinal absorption during the fed state, while other sources of 
circulating glucose derive from hepatic processes (glycogenolysis and gluconeogenesis) 
during the fasting state [7]. The maintenance of circulating glucose levels in a relatively 
narrow range is strictly dependent on glucoregulatory hormones release and activity. 
They include insulin, amylin and glucagon, produced in the pancreatic islets of 
Langerhans, and glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP), known as incretins and derived from the intestine [8]. 
Among the various hormones involved in glucose modulation, insulin and glucagon are 
the most relevant. Insulin is secreted by pancreatic β-cells in response to increased blood 
glucose and amino acids in the postprandial state. Insulin is able to reduce circulating 
glucose levels by enhancing the uptake of glucose into insulin-sensitive cells and 
promoting its storage in liver via glycogenesis (conversion of glucose to glycogen) and 
lipogenesis (fat formation). In addition, insulin inhibits glucagon secretion, thus stopping 
the hepatic production of glucose via glycogenolysis and gluconeogenesis [9]. Glucagon is 
secreted from pancreatic α-cells. It is produced in response to fasting hypoglycemia and 
acts increasing glucose levels by enhancing hepatic glycogenolysis and gluconeogenesis 
[10]. The hormone amylin, released from pancreatic β-cells, contributes to reduce 
glucagon in postprandial state, as well as slowing of gastric emptying. GIP and GLP-1, 
glucose-dependent hormones, are secreted only when glucose levels rise above normal 
fasting glycemia and are involved in the regulation of blood glucose, acting on insulin and 
glucagon release [11]. 
The absorptive state or fed state, which occurs when we consume and digest a meal 
absorbing the nutrients (fats, proteins and carbohydrates), is characterized by increased 
glucose concentrations in the bloodstream, that in turn stimulates pancreatic β-cells to 
release insulin. Postprandially, the secretion of insulin occurs in an initial phase of rapid 
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release of preformed insulin, followed by increased insulin synthesis and release in 
response to blood glucose [7]. Basically, the major factors that influence postprandial 
glucose homeostasis are those affecting the suppression of endogenous glucose release 
and those that concern the hepatic and extrahepatic glucose uptake. Insulin primarily 
stimulates the uptake of glucose mainly by hepatocytes, adipocytes and muscle cells, 
taking advantage of glucose transporters (GLUTs). GLUT2, a high-capacity and low-affinity 
glucose transporter, is highly expressed in the liver, while GLUT4 is detected in insulin 
sensitive tissues such as skeletal and cardiac muscle, brown and white adipose tissue 
[12]. Once inside, glucose is immediately converted into glucose 6-phosphate (G6P), 
leading to a reduction in intracellular glucose levels which further increases glucose 
uptake. At the same time, insulin suppresses both hepatic gluconeogenesis and 
glycogenolysis, responsible for the endogenous glucose production [13] (Fig. 1). 
 
The postabsorptive state or fasting state, occurs when food has been digested, absorbed 
and stored. The drop in blood glucose levels several hours after a meal leads to a 
decrease in insulin release, paralleled with a rise in glucagon secretion from pancreatic α 
cells. Glucagon acts mainly in the liver, where it inhibits the synthesis of glycogen and 
stimulates the glycogenolysis, the breakdown of stored glycogen back into glucose [14]. 
The large amount of glucose derived from glycogen is then released in the circulation to 
be used by the peripheral tissues and the brain. Anyway, muscle and liver start to use 
fatty acids as fuel when the blood glucose levels drop, while the entry of glucose into 
muscle and adipose tissue decreases in response to a low insulin level, contributing to the 
maintenance of the blood glucose homeostasis. Finally, to replace the glycogen stores 
that have been depleted in the liver, the gluconeogenesis allows the generation of 
glucose from non-carbohydrate carbon substrates such as lactate, citric acid cycle 
intermediates, amino acids and glycerol [15]. When fasting is prolonged to the point of 
starvation, glycolysis is shut off in cells that can use alternative fuels, such as skeletal 
muscle cells that switch from using glucose to fatty acids, converting them into acetyl 
CoA, used in the tricarboxylic acid cycle (TCA) cycle to produece ATP. As starvation 
continues, fatty acids and triglycerides stores are used to create ketones bodies, which 
become the major source of fuel for the heart and other organs [16] (Fig. 2).  
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Figure 1. Absorptive State. During the absorptive state, the body digests food and absorbs the nutrients. 
(Anatomy and Physiology - BC Open Textbook project)  
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Figure 2. Postabsorptive State. During the postabsorptive state, the body must rely on stored glycogen for 
energy (Anatomy and Physiology - BC Open Textbook project)  
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1.2 Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease resulting in the destruction of 
pancreatic β-cells and in the consequent development of hyperglycemia, after a 
prolonged and variable latent period. Although T1DM can be diagnosed at any age, it is 
one of the most common chronic diseases of childhood [17]. T1DM is a multifactorial 
disease resulting from a complex interplay between host genetics, immune system and 
environment. Although genetic predisposition are clearly important, the increased 
incidence can only be explained by changes in environment or lifestyle [18]. The presence 
of auto-antibodies against the pancreatic islet cells is the hallmark of T1DM, even if their 
role in the pathogenesis of the disease is still unclear. Beyond islet cells auto-antibodies, 
there are auto-antibodies against insulin (IAA), glutamic acid decarboxylase (GAD, 
GAD65), protein tyrosine phosphatase (IA2 and IA2β) and zinc transporter protein 
(ZnT8A) [19].  
T1DM is clearly a polygenic disorder, with approximately 50 loci known to affect disease 
susceptibility. The human leukocyte antigen (HLA) class II genes show the strongest 
association with T1MD (especially the HLA-DRB1, HLA-DQA1 and HLA-DQB1 loci), as well 
as HLA class I genes, which are responsible for 40–50% of the genetic risk [20]. Moreover, 
multiple non-HLA loci have been reported to contribute to disease risk, including  INS,  
CTLA4,  PTPN22,  IL2RA, IFIH1, CAPSLIL7R,  CLEC16A, and PTPN2 [21]. However, also the 
environment factors play a key role in the pathogenesis of the disease. The main 
environmental factors associated with T1DM are drugs, pollutants, dietary factors, stress, 
infections and gut microbiota [22]. Pentamidine, alloxan and streptozotocin can be toxic 
to β-cells, while among persistent organochlorine pollutants (POPs), dioxins inhibits 
glucose uptake and lowers insulin production [23]. Several studies showed that dietary 
factors are involved in T1DM pathogenesis, including cow’s milk and wheat gluten as risk 
factors, while breastfeeding and Vitamin D seems to have protective effects. The role of 
the psychological stress is still debate but it may induce T1DM associated autoimmunity 
and β-cell stress, thereby accelerating its development [24]. Finally, a number of viral 
infections associate with T1DM onset in humans, including enterovirus, rotavirus and 
cytomegalovirus (CMV) [25]. The mechanisms by which these factors affect T1DM are still 
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unclear. So far, it has been proposed that these environmental factors may induce 
immune responses by generating novel antigens, as well as directly or indirectly inducing 
epigenetic alterations, which regulate gene expression in immune cells [22].  
T1DM is a chronic autoimmune disorder associated with selective destruction of insulin-
producing pancreatic β-cells, histologically characterized by cells inflammation (insulitis) 
and damage. The pathogenesis of β-cells destruction within the islet in T1DM is difficult 
to follow due to the marked heterogeneity of the pancreatic lesions. Although symptoms 
usually occur when 90–95% of β-cells are lost, recent studies suggest that 40%–50% β-
cells viability may be present at the onset of hyperglycemia. The rate of β-cells 
destruction is quite variable, being rapid in some individuals, mainly infants and children, 
and slow in others, such as in adults [26]. The immunological events occurring in T1DM 
involve macrophages, dendritic cells (DCs) and T lymphocytes, both CD4+ and CD8+ T 
cells. Among CD4+ T cells, Th1 and Th17 cells produce proinflammatory cytokines, while 
CD4+ Th2 cells have been recognized to have protective effects against autoimmunity 
[27]. CD4+ T regulatory (Treg) cells exhibit potent regulatory functions and are necessary 
to maintain immune tolerance. In addition to CD4+ T cells, also CD8+ T cells are involved 
in the pathogenesis of T1DM. Studies in NOD mice demonstrated that the activation of 
CD8+ T cells can cause damage to pancreatic islets, contributing to the onset and 
development of the disease [28]. 
The classical symptoms of T1DM, which typically develop over a short period of time, are 
polydipsia, polyuria, enuresis, lack of energy, extreme tiredness, polyphagia, weight loss, 
poor healing, chronic infections and blurred vision, with severe dehydration and diabetic 
ketoacidosis in children and adolescents. In patients with classic symptoms, T1DM is 
diagnosed based on plasma glucose criteria, either the fasting plasma glucose (FPG) or 
the 2h plasma glucose (2h PG) value after a 75g oral glucose tolerance test (OGTT) or 
Hemoglobin A1c (HbA1c). FPG ≥ 126 mg/dL (7.0 mmol/L), 2h PG after OGTT ≥ 200 mg/dL 
(11.1 mmol/L), HbA1c ≥ 6.5% (48 mmol/mol) or a random plasma glucose ≥ 200 mg/dL 
(11.1 mmol/L) along with symptoms of hyperglycemia, are diagnostic of the disease [29]. 
A key distinguishing feature between type 1 and type 2 disorders is the presence of auto-
antibodies against β-cells antigens, observed in more than 90% of subjects with newly 
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diagnosed T1DM. An accurate diagnosis of the disease in childhood and adolescence is 
crucial for optimum care and avoiding complications [30].  
Regarding the management of T1DM, the discovery of insulin in 1921 was clearly the 
most significant therapeutic event in the history of the disease. Currently, the 
administration of exogenous insulin through daily injections or computerized pumps 
remain the most noticeable treatment for T1DM patients [31]. Exogenous insulin 
administration significantly increases life expectancy and helps normalize blood glucose, 
but can expose patients to episodes of hypoglycemia, one of the worst side effects of this 
treatment [31]. Recently, notable progresses have been made in the development of 
immunotherapy approaches using pharmaceutical compounds, such as cyclosporine. 
These compounds are designed to manipulate the immune system in order to avoid β-cell 
destruction, successfully blocking the progression of the disease [32]. Alternative 
immunotherapy methods, including autoantigen-specific immune therapy, immuno-
regulatory-based approach and activation of Treg cells, have been proposed and are 
currently in preclinical and clinical studies [33]. In some cases, whole pancreas or islet 
transplantations can be effective for T1DM treatment, even though they are limited by 
donor scarcity and life-long immunesuppression. Therefore, development of novel 
therapies that can tackle these issues is highly desirable [34]. 
 
Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder characterized 
by relative (rather than absolute) insulin deficiency, peripheral insulin resistance and 
consequent hyperglycemia. In 2013, the global prevalence of T2DM in adults (20-79 years 
old) was 8.3% (382 million people) and this number is expected to rise beyond 592 million 
by 2035 [35]. More than 90-95% of diabetes patients belong to T2MD and most of these 
patients are adults. However, the number of young people (< 20 years) with the disease is 
rapidly increasing, mainly due to changes in the lifestyle of children in terms of more 
sedentary life and less healthy food [36]. T2DM is indeed characterized by a strong 
genetic predisposition, even though the environmental factors also play a key role in this 
types of disorder [37]. 
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Despite several genome-wide association studies (GWAS) have identified a large array of 
gene mutations and single nucleotide polymorphisms (SNPs) associated with T2DM, these 
variants explain less than 15% of disease heritability [38]. A study conducted in different 
countries on T2DM patients identified various diabetes putative loci positioned in and 
around the CDKAL1, CDKN2A/B, HHEX/IDE and SLC30A8 genes, providing strong 
evidences that common genetic determinants, including common specific genes, are 
linked to diabetes [39, 40]. Genetic variants and polymorphisms in the interleukin and 
related genes, including interlukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) genes, 
were found to be associated with increased risk of developing T2DM [41]. Interestingly, 
also variants and SNPs in the antioxidant genes, such as superoxide dismutase and 
glutathione peroxidase, are implicated in the risk and pathogenesis of T2DM [35]. 
However, beyond the genetic causes, environmental and lifestyle changes significantly 
contribute to the rapid global increase in T2DM prevalence and incidence in recent 
decades. It has been demonstrated that an unhealthy energy-dense diet in association 
with a sedentary lifestyle are the primary cause of obesity and T2DM [42]. Despite the 
wide range of diet types consumed worldwide, generally plant food is associated with 
reduced T2DM risk than meat, while refined grains or sugar-sweetened beverages appear 
to promote obesity and diabetes risk [43]. Unfortunately, epidemiological studies cannot 
exclude the impact of confounding factors such as those of physical activity, which is 
difficult to assess in queries or interviews. Indeed, high total physical activity is associated 
with a reduction in relative diabetes risk by approximately 30%, compared to low one 
[44]. Other contributing factors for T2DM are the duration and quality of sleep, paralleled 
with housing environment such as the exposure to residential traffic, noise, fine airborne 
particulate, UV or ionising radiation, toxins or allergens [43]. The relationship between 
depressive mood, stress or infections and diabetes is still debated. Of note, except high 
levels of nutrients and their metabolites in blood, only few environmental or lifestyle 
factors directly affect β-cell function. They usually have different sites of action, such as 
the immune system, vascular tissue, adipose tissue, liver, muscle, brain or intestine [43]. 
Regarding the pathophysiology, T2DM is characterised by hyperglycemia, insulin 
resistance and relative pancreatic β-cell failure, with up to 50% cell loss at diagnosis. 
More than 90-95% of T2DM patients are adults, even though recently the incidence of 
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this disease in young people is significantly increased, where the β-cell loss occurs more 
rapidly compared to adults [45]. Insulin resistance is a pathological condition in 
which cells fail to respond normally to insulin and occurs primarily within hepatocytes, 
adipocytes and myocytes. As a consequence, insulin resistance increases the demand for 
insulin in these tissues, leading to an initial period of euglycaemic hyperinsulinaemia [46]. 
Subsequently, insulin secretion decreases with the increased demand for insulin by time 
due to the gradual destruction of β-cells, causing some T2DM patients to be dependent 
on insulin [47]. Increasing evidences support that T2DM is strongly modulated by β-cell 
dysfunction and apoptosis, mainly due to a glucose toxicity effect. Particularly, 
hyperglycemia-induced β-cell apoptosis has been extensively studied regarding the 
balance between pro-apoptotic Bcl-2 proteins (Bad, Bid, Bik, and Bax) and anti-apoptotic 
Bcl family (Bcl-2 and Bcl-xL). Apoptosis occurs when the concentration of pro-apoptotic 
proteins exceeds that of anti-apoptotic ones [48]. 
The classical symptoms associated with T2DM, which usually come on slowly, 
include increased thirst, frequent urination, unexplained weight loss, increased hunger 
and tiredness. The long-term complications caused by high blood glucose levels are heart 
disease, strokes, diabetic retinopathy, kidney failure and reduced blood flow in the limbs, 
which may lead to amputations. As described for T1DM, T2DM is diagnosed using either 
the estimation of plasma glucose (FPG or OGTT) or HbA1c. FGP ≥ 126 mg/dL (7.0 mmol/L), 
2h PG after OGTT ≥ 200 mg/dL (11.1 mmol/L), HbA1c ≥ 6.5% (48 mmol/mol) or a random 
plasma glucose ≥ 200 mg/dL (11.1 mmol/L) along with symptoms of hyperglycemia are 
diagnostic of the disease [35]. Of note, HbA1c has the advantage to be a stable diagnostic 
measure that does not require fasting and is equivalent to FPG regarding the prediction of 
the development of retinopathy [49]. T2DM can be distinguished from T1DM considering 
that it is characterized by hyperglycemia in the context of insulin resistance and relative 
insulin deficiency, while in T1DM there is an absolute insulin deficiency due to destruction 
of pancreatic islet cells. However, if the diagnosis is in doubt, antibody testing may be 
useful to confirm T1DM [50].  
Management of T2DM mainly focuses on lifestyle interventions and pharmacological 
treatments, in order to reach the goal of HbA1c around 7% or fasting glucose <130 mg/dL. 
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Considering that around 60% of patients with T2DM are obese (BMI ≥30 kg/m2) and show 
insulin resistance, diet and lifestyle are effective tools for T2DM prevention and 
management [51].  Regarding the pharmacological management, the initial T2DM 
management approach recommend monotherapy, usually with metformin, but if the 
HbA1c goal has not been met within approximately 3 months of starting initial therapy, 
treatment should be intensified by adding a second or third agent [52]. Metformin 
reduces hepatic glucose production, enhances peripheral insulin sensitivity and stimulates 
GLP-1 secretion. Moreover, it effectively decreases HbA1c levels, is weight neutral, does 
not cause hypoglycemia and can have modest beneficial effects on blood pressure and 
lipid profile [42]. Sulfonylureas, which act on β-cells promoting insulin secretion [53], and 
thiazolidinediones, that stimulate peroxisome proliferator-activated receptors (PPARs), 
are usually chosen for dual therapy [54]. Glucagon-like peptide-1 receptor agonists (GLP-1 
RAs) are synthetic analogues of the native human GLP-1 with improved pharmacokinetic 
properties. They trigger GLP-1-like effects, including increased insulin secretion, reduced 
glucagon released, reduced hepatic glucose output, delayed gastric emptying and 
increased satiety [55]. Dipeptidyl peptidase 4 (DPP-4) inhibitors, such as sitagliptin, 
saxagliptin and alogliptin, act reducing the enzymatic degradation of the incretin 
hormones GLP-1 and GIP. This leads to an increased availability of endogenous incretins, 
stimulating insulin secretion from pancreatic β-cells and inhibiting glucagon release from 
pancreatic α-cells in a glucose-dependent manner  [56]. Finally, insulin remains the most 
potent glucose-lowering agent, particularly for patients with high HbA1c levels. However, 
there are multiple barriers to initiating insulin therapy and the decision to add insulin will 
require discussion between the prescribing physician and the patient, taking into 
consideration the patient's motivation, general health, age, risk of hypoglycemia and 
cardiorenal complications [57]. 
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2. Glucose metabolism: focus on insulin 
The pancreas is a centralized organ vital for whole body metabolic homeostasis and the 
nutrient metabolism in pancreatic cells is not only essential for providing them energy, 
but also acts as a mechanism to sense and react to circulating levels of macronutrients. 
The pancreas, located behind the stomach and connected to liver, spleen and small 
intestine, produces exocrine enzymes to aid digestion and endocrine hormones to 
regulate blood glucose. The exocrine pancreas represents around 98% of the pancreatic 
mass and is responsible for synthesis, storage and secretion of digestive enzymes into the 
duodenum. The endocrine pancreas, representing about 2% of the total mass, is made up 
of the islets of Langerhans, containing different cell types: α- β- δ- ε- and γ (PP) cells [58]. 
Adult pancreatic β-cells express and secrete insulin in response to relevant stimuli. 
Despite the primary regulatory factor for insulin synthesis and secretion is glucose, other 
stimuli, such as amino acids, fatty acids, hormones and neuronal signals, also play 
important roles in these processes. Once released in blood stream, insulin binds to its 
receptor found in several tissues, especially in liver, muscle and adipose tissue, to 
facilitate glucose uptake and storage. An efficient energy metabolism in pancreatic β-cells 
is necessary to prevent dysfunction of this metabolic framework, such as T2DM, whose 
prevalence has been dangerously increasing over the past few decades [59]. 
 
2.1 Insulin structure and biosynthesis 
Insulin was the first peptide hormone to be discovered. In the mid 1950′s Sanger showed 
that insulin is a two-chain heterodimer, consisting of a 21 amino acid residue “A” chain 
and a 30 amino acid residue “B” chain, bound by two disulfide linkages (A7-B7 and A20-
B19) [60]. Although this primary structure provided important information concerning the 
amino acid composition and size of the molecule (5,8 kDa), questions regarding the 
processes of insulin biosynthesis and secretion remained unclear until the late 1960′s, 
when proinsulin was discovered [61]. This precursor protein (   9 kDa) consists of both the 
A and B chain, joined through an intervening fragment, known as C-peptide. Finally, only 
in 1976 Chan et al. demonstrated that there was an additional and larger precursor of 
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insulin, preproinsulin. This single-chain polypeptide (  12 kDa) consists of proinsulin 
extended at the amino-terminus by a 24-residue signal peptide [62].  
 
 
Figure 3. Insulin synthesis and maturation. (2004 Beta Cell Biology Consortium) 
 
Preproinsulin, once encoded, is translocated across the rough endoplasmic reticulum 
(rER) membrane into the lumen, via interactions of its signal peptide with the signal 
recognition particle (SRP) and SRP-receptor in the rER membrane [63]. On the lumenal 
side of the rER membrane, the preproinsulin signal peptide is cleaved  to yield proinsulin, 
which undergoes folding and formation of three disulfide bonds to generate the native 
tertiary structure, the direct precursor of insulin. Finally, the folded proinsulin is 
transported from the ER to the Golgi apparatus where it enters immature secretary 
vesicles and is cleaved to yield insulin and C-peptide. Insulin and C-peptide are then 
stored in these secretory granules together with islet amyloid polypeptide (IAPP or 
amylin) and other less abundant β-cell secretary products [64]. Both proinsulin and insulin 
monomers tend to form dimers when their concentration rises, while in the presence of 
zinc (Zn) and favorable pH the monomers assemble into hexamers [65]. The hexamer, 
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despite it is inactive, presents long-term stability, which protects the highly reactive 
insulin, yet readily available. Once the hexamers are secreted from the β-cell and diffuse 
into circulation, a combination of electrostatic repulsion and decreased concentration of 
insulin favors the dissociation of insulin into its active monomeric form [66].  
 
2.2 Regulation of insulin transcription 
Insulin content in β-cells is highly dynamic, enhancing in the presence of nutrients and 
decreasing in response to fasting. This ability of β-cells to rapidly respond to cellular 
signals is mainly due to transcriptional regulation. Several elements within the promoter 
region of insulin gene (A, C, E, Z, and CRE elements) provide binding sites for different β-
cell transcription factors that regulate insulin gene expression [67]. The A elements 
contain a TAAT motif in the core region, that represents the central DNA binding 
recognition site for several proteins, including duodenal homeobox-1 (PDX-1), Cdx2/3 and 
Isl-1 [68]. The expression of PDX-1, which was initially characterized as an insulin and 
somatostatin transcriptional factor, is generally restricted to islet β-cells (~91%) in adult 
pancreas. Cdx2/3, despite it is expressed both in β-cells and α-cells, appears to play a less 
important role in islet function, because Cdx2/3 KO mice presents defects only in 
intestinal function. Isl-1, which is expressed by all types of islet cells and plays an essential 
role in islet formation during embryo development, is able to activate somatostatin, 
glucagon and IAPP gene expression [59]. There are two C elements in the insulin gene 
promoter, C1 and C2 element. Rat insulin promoter element 3b (RIPE3b)1 is the major 
factor binding the C1 element, which has been demonstrated to play a key role in 
regulating insulin transcription [69]. The C2 element contributes to insulin, glucagon and 
somatostatin transcription in α-, β-, and δ-cells, respectively. In particular, the activator of 
insulin C2 element PAX6, a member of the Pax transcription factor family, which is 
required for normal transcription of these genes and islet development [70]. Regarding 
the E elements, rodents have two separated mini-enhancer units within the insulin gene, 
while other mammals have only one. The most important E element activators are 
BETA2/NeuroD1, E2/5, E12 and E47 [71]. Pancreatic islets are especially enriched in 
BETA2/NeuroD1, which is fundamental in regulating insulin gene expression and β-cell 
survival [72]. The Z element is located upstream of the A element and is present only in 
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the human insulin gene promoter. Of note, recent studies demonstrated that A element 
activation depends on the present of the Z element. The Z element functions as both a 
potent glucose-responsive transcriptional enhancer in primary cultured islet cells and as a 
transcriptional repressor in transformed β-cell lines and primary fibroblast cells [73]. 
Finally, the human insulin gene promoter contains 4 Cyclic AMP response element (CRE) 
sites: CRE1, CRE2, CRE3 and CRE4, which contain within the core a sequence similar to the 
CRE consensus sequence. Several transcription factors, that are members of the CRE 
binding protein (CREB)/ATF family, regulate insulin gene transcription by binding to the 
consensus CRE [74].  
 
2.3 Regulation of insulin translation 
Glucose metabolism is no doubt the most influential physiological event that stimulates 
insulin gene transcription and mRNA translation, despite insulin biosynthesis depends on 
multiple factors. In response to nutrients, β-cells are able to enhance their overall protein 
translation, which is mostly controlled by the phosphorylation/dephosphorylation of 
eukaryotic initiation factor 2a (eIF2a).  Protein phosphatase 1 (PP1) is responsible for the 
eIF2a dephosphorylation, while the pancreatic ER kinase (PERK) phosphorylates eIF2a, 
thereby regulating insulin translation [75]. Interestingly, PERK seems to be required 
during the fetal and neonatal phases for proper development of β-cell mass, while not 
necessary in adults for maintaining β-cell mass [76]. Moreover, β-cells have developed a 
mechanism for detecting the amount of insulin stored in granules and secreted, in order 
to adjust insulin synthesis accordingly. For example, the islet cell autoantigen 512 
(ICA512), a granule transmembrane protein, plays a crucial part in this feedback control. 
When the granule membrane fuses to the cell membrane to release insulin, the cytosolic 
fragment of ICA512 is released from granules and targets the transcriptional factor STAT5 
in the nucleus, which in turn upregulates insulin transcription [77]. Therefore, the release 
of insulin from secretory granules is rapidly communicated to the nucleus, which serves 
as a positive feedback mechanism to start insulin translation, in order to maintain a 
sufficient amount of stored insulin [59]. 
In addition, β-cells also adjust insulin production in response to immediate environmental 
triggers by modulating the speed of insulin translation. The acute glucose-stimulated 
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insulin production is independent of mRNA synthesis within the first 45min, considering 
that blockage of transcription occurs only after that time frame. For example, when rat 
islets are exposed to 25 mM glucose for 1h, occurs a significant induction in intracellular 
proinsulin levels, while proinsulin mRNA content remains almost the same [78]. 
Moreover, insulin mRNA stability, which depends on nutrient status, is a crucial factor 
that influences insulin biosynthesis. In particular, both in vitro and in vivo studies 
demonstrated that insulin mRNA stability decreases under lower glucose levels and 
increases under high glucose conditions. Rats fasted for 3 days present only 15–20% of 
the pancreatic insulin mRNA measured in the control animals. Thus, translation regulation 
controls the immediate insulin synthesis, while regulation at the transcriptional level 
contributes to the modulation of delayed insulin synthesis [59].  
 
2.4 Regulation of insulin secretion 
Secretion of insulin from β-cells represents a crucial step in the regulation of glucose 
homeostasis and in healthy subjects it precisely meet the metabolic demand. However, 
abnormalities in insulin secretion have been demonstrated to be an integral component 
of both T1DM and various forms of T2DM. Insulin is stored in large dense granules and 
released by exocytosis, trough a multistep process that involves the transport of the 
secretory vesicles to the plasma membrane, then docking, priming and finally their fusion 
with the plasma membrane. Only a small part of the insulin stored in granules is released, 
even under maximum stimulation, suggesting that systemic insulin levels are regulated by 
secretion rather than by biosynthesis [66]. To sense the nutritional state, β-cells are 
clustered in islets strategically connected to the circulation, which allows them to receive 
a greater amount of blood than cells in the surrounding exocrine regions. In addition to 
glucose, some amino acids and fatty acids impact on insulin secretion, a process that is 
modulated cooperatively by nutrients, hormones and neurotransmitters in association 
with electrical depolarization of the β-cells [59] (Fig. 4). 
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Figure 4. Schematic illustration of nutrient-regulated insulin secretion [59]. 
Glucose, that accumulates immediately after food ingestion, is no doubt the primary 
stimuli for insulin release in several animal species. In rodents and humans, the amplitude 
of insulin secretion induced by glucose is significantly larger compared with that 
stimulated by protein or fat. While glucose is the obligate fuel source for brain, other 
tissues, such as pancreas, can use alternative fuel sources during starvation, an 
adaptation that could predispose them to glucolipotoxicity [79]. 
β-cells contain several sensing devices that measure circulating glucose, including glucose 
transporter 2 (GLUT2), which is the major glucose sensor in these cells. GLUT2 is the only 
glucose transporter expressed in β-cells and its mobilization to the plasma membrane is 
insulin-independent. Once inside β-cells, glucose is phosphorylated by the rate-limiting 
enzyme glucokinase, which acts as a glucose sensor [80]. The endpoint of glycolysis is the 
metabolic substrate pyruvate which is subsequently oxidized through the TCA cycle to 
produce ATP. This process is the major signaling pathway coupled to “ATP-sensitive 
potassium (KATP) channel-dependent insulin release”, which leads to an increased 
intracellular ATP/ADP ratio, associated with closure of KATP channels, depolarization of 
the plasma membrane, opening of voltage-dependent Ca2+channels and activation of 
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exocytosis of insulin-containing granules. Interestingly, also some products derived from 
the anaplerosis/cataplerosis can act as insulin secretion signals, including NADPH, 
malonyl-CoA, and glutamate [81].  
Single amino acids, at physiological concentrations, are usually poor insulin 
secretagogues, but certain combinations of amino acids or higher levels can enhance 
glucose stimulated insulin secretion (GSIS). For example, during fasting proteins in 
skeletal muscle are catabolized and amino acids, such as alanine and glutamine, are 
released into circulation. These free amino acids acts as potent glucagon secretagogues, 
leading to an elevation in blood glucose levels, which then triggers insulin secretion [82]. 
Dietary amino acids can also induce insulin secretion via incretin-dependent mechanisms. 
GIP and GLP-1, the two major incretin hormones secreted from the gastrointestinal tract, 
directly act on β-cells by binding to their specific cell-surface receptors, augmenting GSIS 
[83]. Beyond glucose and amino acids, also free fatty acids (FFAs) can influence β-cell 
secretion of insulin. In T2DM, FFAs potentiate insulin secretion to compensate the 
increased insulin need consequently of insulin resistance [84].  
Finally, several hormones are able to modulate insulin secretion. Despite β-cells are not 
considered classic estrogen targets, their receptors are present in islets and the effects of 
17β-estradiol on β-cells are well described. At physiological concentrations, 17β-estradiol 
significantly decreases KATP channel activity, which causes membrane depolarization and 
subsequent opening of voltage-gated Ca2+ channels, influencing insulin secretion [85]. 
The effect of melatonin, a hormone secreted by the pineal gland, on insulin secretion is 
controvertial, despite melatonin receptors (MTNRs) has been discovered on both clonal 
β-cells and human islets [86]. GLP-1, secreted from small intestinal L-cells in response to 
nutrient load, is involved in insulin secretion in order to meet the increased demand for 
insulin after a meal. Analogs of GLP-1 have been studied as a potential therapy for T2DM 
for many years, with the long-lasting GLP-1 analog exenatide introduced to clinics in 2005. 
Upon activation of the GLP-1 receptor (GLP-1R), adenylyl cyclase is activated, leading to 
the generation of cAMP, which significantly potentiates GSIS [87]. Leptin, secreted by 
adipocytes, exerts an inhibitory effect on insulin secretion. Indeed, has been 
demonstrated that leptin deficiency is associated with hyperinsulinemia in both mice and 
humans [88]. 
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2.5 Insulin receptor and its signal transduction network 
Although insulin is generally viewed as a glucose homeostasis regulating hormone, 
actually it is known to have a much extended pleiotropic role. Insulin acts through a 
receptor located in the membrane of several target organs and tissues, including β-cells. 
The insulin receptor (IR) belongs to the receptor tyrosine kinase (RTK) superfamily, whose 
members generally regulate several cellular functions, including cell proliferation, 
survival, differentiation, migration and metabolism [89]. The receptor, synthesized as 
single chain preproreceptors, is processed into α and β chains by a furin-like proteolytic 
enzyme and subsequently glycosylated, folded and dimerized to yield the mature form. 
Each monomer is structurally organized into 8 distinct domains: a leucine-rich repeat 
domain (L1), a cysteine-rich region (CR), an additional leucine rich repeat domain (L2), 
three fibronectin type III domains (FnIII-1, FnIII-2 and FnIII-3), an insert domain inside 
FnIII-2 (ID, containing the α/β furin cleavage site), a transmembrane helix (TH) and 
intracellular juxtamembrane (JM) region, just upstream of the intracellular tyrosine kinase 
(TK) catalytic domain, responsible for subsequent intracellular signaling pathways [66]. 
Insulin, IGF-I and IGF-II bind to the α-chain of the IR inducing structural changes within the 
receptor, which leads to the autophosphorylation of the tyrosine residues within the 
intracellular TK domain of the β-chain. These changes create binding sites for signaling 
protein partners containing src-homology 2 (SH2) domains or phosphotyrosine-binding 
(PTB) domains. Unlike other RTKs, IR do not bind signaling proteins directly, but works 
through key signaling intermediates, the insulin receptor substrate (IRS) proteins  as well 
as the adapter Shc (SH2 domain containing). The IRS proteins are a family of cytoplasmic 
adaptor molecules that transfer signals from the IR to evoke a cellular response [90]. The 
central portion and the C-terminal domain of the IRS proteins contain up to 20 potential 
phosphorylation sites that bind to signaling proteins containing SH2 domains, when 
phosphorylated by the IR. The two major IR signaling cascades are the PI3K/AKT pathway 
and the Grb2-SOS-Ras-MAPK (also known as ERK) pathway. The PI3K pathway is 
responsible for most metabolic effects of insulin and is connected exclusively through IRS. 
On the contrary, the ERK pathway, linked both with IRS and Shc, is involved in the 
regulation of gene expression and, together with the PI3K pathway, in the control of cell 
growth (mitogenesis) and differentiation [91]. 
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3. Factors influencing beta cell function 
The pancreas and especially β-cells play crucial roles in maintaining whole body energy 
balance. Nutrient metabolism in β-cells is not only essential for providing them energy, 
but also allow them to sense and respond to circulating levels of macronutrients, putting 
pancreatic metabolism central in the regulation of whole body energy homeostasis. Many 
factors could affect pancreatic β-cells function, such as hyperglycemia/glucotoxicity, 
lipotoxicity, autoimmunity, inflammation, adipokines, incretins and insulin resistance [92]. 
In particular, chronic hyperglycemia may result in deleterious effects on insulin synthesis 
and secretion, cell survival and insulin sensitivity. Moreover, in the presence of 
hyperglycemia, extended exposure to increased free fatty acids (FFAs) leads to the 
accumulation of toxic metabolites into the cells (lipotoxicity), causing decreased insulin 
gene expression and impaired insulin secretion. In addition recent studies, focusing on 
nonalcoholic fatty pancreas disease (NAFPD), demonstrated that the accumulation of 
FFAs within the pancreas, possibly due to inefficient lipid metabolism, disrupts insulin 
secretion and may contribute to the development of the disease [58].  
 
3.1 Beta cell physiology 
β-cells represent the most important glucose sensors among pancreatic cell types and 
their function is absolutely necessary for proper glucose balance within the whole body. 
In healthy subjects, glucose enters β-cells through facilitated diffusion via GLUT2. Once 
inside, glucose is metabolized to generate pyruvate and NADH via glycolysis, which in turn 
are used to produce ATP through the TCA cycle and the oxidative phosphorylation. The 
resulting increased ATP/ADP ratio causes the fusion of insulin granules with the plasma 
membrane, promoting the hormone release into the circulation [93]. Several studies, 
both in vitro and in vivo, convincingly demonstrated the importance of nutrient 
metabolism for β-cell function and the key role of mitochondria for an efficient GSIS. For 
example, the deficiency of dynamin-related protein 1 (DRP1) in β-cells, that prevents 
mitochondrial fission, reduces GSIS limiting substrate availability to mitochondria. Of 
note, GSIS is rescued in these cells by the simple addition of pyruvate, suggesting that 
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mitochondrial dynamics is able to impact metabolic pathways outside of the 
mitochondria, including glycolysis [94].  
Besides glucose, β-cells respond to several macronutrients such as other 
monosaccharides, amino acids and FFAs, as well as to hormones and neurotransmitters. 
For example, although fructose is largely metabolized in liver, mouse and human β-cells 
secrete insulin in response to fructose, when it interacts with the sweet taste receptor 
type 1 (T1R2) on the β-cell membrane [95]. Amino acids are essential nutrients for β-cells, 
with both positive and negative effects on insulin release, depending on time, 
concentration and type [58]. FFAs modulate insulin secretion via different metabolic 
signalling mechanisms. Once inside β-cells, FFAs are converted into FA-CoA and can enter 
the glycerolipid/FFA cycling (lipogenesis and lipolysis) or can be oxidized to acetyl-CoA to 
enter TCA cycle. In order to improve ATP production, metabolites produced in these 
pathways can independently modulate insulin release through other parallel mechanisms 
[96].  
In addition to nutrients, also circulating hormones interfere with the modulation of β-cells 
metabolism. Non-pancreatic hormones, such as the incretins GLP-1and GIP, are important 
for glucose homeostasis. They are both released from the intestine in response to food 
intake and activate their corresponding G-protein-coupled receptors (GLP-1R or GIPR) on 
the surface of β-cells [97]. GLP-1 and GIP are able to stimulate insulin secretion  when 
glucose is high, but is still debate if this directly depends on their effects on nutrient 
metabolism in β-cells. Recent evidences suggest that GLP-1 and related peptides have 
beneficial effects on mitochondrial metabolism, biogenesis and reactive oxygen species 
(ROS) production in different cell types [58].  
 
3.2 Dysfunctional beta cells  
Nowadays, western diets and sedentary lifestyle represent the major contributors to 
obesity and insulin resistance, which are strictly associated with metabolic syndrome. 
Pancreatic β-cells, which are the primary nutrient-sensors in our bodies, respond to 
chronically higher-than-normal levels of circulating nutrients increasing in mass, in order 
to compensate for higher insulin requirements. However, the slow rate of proliferation 
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and regeneration of this highly differentiated cells is not enough to completely maintain 
glucose homeostasis [58]. High levels of circulating glucose and lipids have also their own 
detrimental effects on β-cells (gluco/lipotoxicity), while inflammation associated with 
obesity, both in peripheral tissues and in pancreas, negatively impacts on β-cell function. 
In addition, stress caused by increased mitochondrial metabolism leads to over-
production of ROS, thus damaging DNA and proteins. Taken together, these insults 
ultimately lead to β-cell failure and death, triggering dependence on exogenous insulin 
for maintenance of glucose balance [98].  
3.2.1 Hyperglycemia and glucotoxicity 
Pancreatic β-cells are very sensitive to blood glucose levels and changes in its 
homeostasis strongly influence their function and dynamics. Several studies have 
demonstrated that the chronic exposure to abnormally high blood glucose has 
deleterious effects on insulin synthesis and secretion, cell survival and insulin sensitivity 
through different mechanisms. In turn, this glucotoxicity leads to hyperglycemia and 
finally to the vicious circle of endless deterioration of β-cells function. Glucotoxicity 
impacts irreversibly the cellular pathways of insulin production and secretion, as opposed 
to beta cell desensitization and beta cell exhaustion, which are reversible. Chronic 
hyperglycemia is able to impair β-cells function and cause β-cells apoptosis through 
multiple pathways and mechanisms [99].  
Firstly, prolonged exposure to increased glucose levels leads to a reduced activity of key 
regulators of insulin promoter activity and other β-cells specific genes, causing a gradual 
loss of insulin gene expression. These processes are, at least in part, mediated by 
oxidative stress. Indeed, long-term sustained hyperglycemia, that increases the metabolic 
flux into the mitochondria, induces a massive production of reactive oxygen species (ROS) 
[100]. In hyperglycaemic conditions, ROS are excessively produced by mitochondrial 
oxidative phosphorylation during anaerobic glycolysis and through alternative pathways, 
which occur when the glycolytic capacity is exceeded. The oxidative stress subsequently 
activates different stress-induced pathways in β-cells, inducing dysfunctional insulin 
biosynthesis and secretion, and ultimately apoptosis [101]. Recent data show a closely 
correlation between the oxidative stress and ER stress. Cellular ROS can increase the 
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accumulation of misfolded proteins in the ER, which amplifies ROS production that in turn 
further enhances the ER stress, impairing insulin production and favoring cell death. The 
ER stress is also induced by β-cells exposure to an increased insulin secretory request 
during hyperglycaemic condition, which increases the demand on ER for the synthesis of 
proinsulin. Despite ER stress triggers the unfolded protein response (UPR) in order to 
restore the ER homeostasis, in case of severe ER stress and strong UPR, apoptosis occurs 
β-cells [92]. Besides ER stress, several studies indicate that chronic hyperglycemia is 
associated with decreased number of mitochondria and changes in their morphology, 
such as increased volume, reduction of the proteins in the inner membrane and increased 
variability in mitochondrial size [102]. Finally, evidence exists that chronic hyperglycemia 
induces non-immune mediated inflammatory pathways, enhancing the production of 
interleukin (IL)-1β, nuclear factor-kB (NF-kB) and Fas receptor in β-cells, even though this 
requires to be confirmed [92].  
3.2.2 Lipotoxicity 
Lipids, which represent no doubt a vital energy source for β-cells, can exert both positive 
and negative effects on their survival and insulin secretory function, depending on 
concentration, duration and glucose abundance. Indeed, prolonged lipid exposure has 
been recently shown to activate cell stress responses including oxidative stress, ER stress 
and autophagy. For example, diabetes is often associated with changes in lipoprotein 
profiles and increased FFA concentrations. Chronic exposure to FFAs determine many of 
the key features of β-cells failure, including apoptosis, defective pro-insulin processing, 
diminished insulin content and gene expression and subsequent reduced GSIS [103]. For 
example, evidence suggests that the uncoupling protein-2 (UCP-2), a ubiquitously 
expressed mitochondrial carrier that uncouple the respiratory chain from ATP synthesis, 
plays a role in lipotoxicity. UCP-2 KO mice are characterized by increased circulating 
insulin levels and are protected from genetic and nutritional diabetes, while UCP-2 
expression is increased in β-cells derived from high-fat feeding rodents [104]. Prolonged 
exposure to FFAs is also able to impair insulin gene expression in the presence of high 
glucose. In particular, palmitate inhibits insulin gene transcription modulating the activity 
of pancreatic duodenal homeobox 1 (PDX-1), a transcriptional factor that plays a central 
role in β-cells function and survival. In vitro, saturated FFAs induce β-cell apoptosis, while 
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unsaturated ones are usually protective, probably due to their greater ability to form 
intracellular triglycerides. Several mechanisms have been proposed to mediate FFAs 
induced apoptosis in β-cells, including ceramide formation, generation of oxidative stress 
and inflammation. In insulin secreting cells, palmitate, but not oleate, induces markers of 
ER stress, causing alterations in its morphology [104] (Fig. 5).  
 
 
Figure 5. Mechanisms of β-cell lipotoxicity: FFA leading to oxidative stress/ER stress/inflammation, resulting 
in β-cell failure. [105] 
 
Although most of the studies have been focused on the effects of FFAs on β-cells 
function, emerging data suggest that cholesterol and lipoprotein fractions may also play a 
role in the progression of β-cells failure. LDL, oxidized LDL and VLDL reduce preproinsulin 
expression levels in isolated β-cells, while HDL particles seems to be protective [106]. 
Interestingly, despite the role of cholesterol in β-cells is still debate, recent findings 
indicate it as an important modulator of β-cells function and survival. The disruption of 
cholesterol transport by reduced function of the ATP-binding cassette (ABC) transporters 
ABCA1 and ABCG1 results in increased fasting glucose levels and impaired glucose 
tolerance. The combined deficiency of ABCA1 and ABCG1 also leads to a significant islet 
inflammation, underlined by enhanced expression of IL-1β and macrophage infiltration 
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[107]. More recently, also the liver X receptor (LXR) alpha, a receptor for cholesterol-
related compounds, is demonstrated to be crucial for insulin secretion. LXRα, 
upregulating the sterol regulatory element-binding protein 1c (SREBP1c), has been 
demonstrated to interfere with glucose metabolism, ATP production and calcium channel 
flux in β-cells [103]. Hao et al. showed a new possible potential mechanism linking 
cholesterol with glucose homeostasis. They demonstrated that excess cellular cholesterol 
is directly linked to reduced GSIS and that normal secretion could be restored by 
cholesterol depletion. The cholesterol regulation of GSIS may involve modification of 
neuronal NO synthase (nNOS) and glucokinase (GK) activity through cholesterol-rich 
membrane microdomains on the insulin granules [108]. Moreover, considering that in β-
cells insulin granules are the major sites of intracellular cholesterol accumulation, excess 
cholesterol is specifically delivered to granules, where it causes their enlargement and 
retention [109]. 
3.3.3 Inflammation and autoimmunity 
The role of autoimmunity in T1DM has been long recognized, however reports have 
shown that about 10% of subjects with T2DM present diabetes-specific autoantibodies, 
with a higher percentage in young people. These evidences suggest a possible role of 
immune system also in the pathogenesis of T2DM. Although the mechanisms and the 
factors behind autoimmunity might be different, the immune-cell infiltration in pancreatic 
islets and the increased production of local cytokines are common of both types of DM 
[110]. β-cells are metabolically and immunologically up-regulated when functionally 
stressed by hyperglycemia. Indeed, in T2DM, chronic metabolic stress such as high levels 
of blood glucose and FFAs, induces an inflammatory response in β-cells, increasing the 
production of cytokines and chemokines. Among them, IL-1β plays a crucial role, 
regulating in turn many other pro-inflammatory cytokines, cytotoxic factors and 
chemokines. IL-1β also contributes to apoptosis and β-cells function impairment [111]. 
Additionally, adipose tissue-derived factors, such as pro-inflammatory adipokines, 
present local and systemic effects on metabolism and contribute to the chronic 
inflammatory process, which triggers β-cells death and is a risk factor for autoimmunity. 
Indeed, apoptotic β-cells may themselves present antigens and stimulate the 
development of an autoimmune response [92]. 
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4. PCSK9 
Proprotein convertase subtilisin kexin type 9 (PCSK9) is the ninth and last member 
belonging to a particular family of proteases known as the proprotein convertases (PCs), 
which includes 8 other members sharing identities to bacterial subtilisin and yeast kexin 
(PC1/3, PC2, Furin, PC4, PC5/6, Pace4, PC7 and SKI-1/S1P) [112]. PCSK9, originally called 
neural apoptosis-regulated convertase 1 (NARC-1), was discovered in primary cerebellar 
neurons, where it plays an important role in brain development as well as in cortical 
neuron differentiation. At the same time, Abifadel et al. identified two mutations in the 
PCSK9 gene associated with autosomal dominant hypercholesterolemia (ADH), in two 
French families without mutations in the candidate genes encoding LDL receptor (LDLR) 
and apolipoprotein B (apoB) [113]. Structural and functional studies revealed that the 
clinical output of these functional variations in PCSK9 gene were linked to an enhanced 
degradation of LDLR. These observations highlighted a strong association between PCSK9 
and circulating levels of LDL-C and quickly other PCSK9 mutations were described around 
the world. The identification of both loss-of-function (LOF) mutations linked to low LDL-C 
levels and gain-of-function (GOF) mutations causing hypercholesterolemia, revealed that 
PCSK9 consistently contribute to the regulation of cholesterol homeostasis. Even if the 
frequency of PCSK9 mutations in patients affected by familial hypercholesterolemia (FH) 
is low (1–2%), these findings established PCSK9 as one of the most promising target for 
the development of new therapies in the treatment of hypercholesterolemia [3]. 
Nevertheless, further analysis on the global physiological function of PCSK9 still have to 
be evaluated, since this protein may have unknown roles beyond LDL-C lowering.  
 
4.1 Structure, cellular biology and targets: focus on LDLR 
Human PCSK9 gene is located on the small arm of chromosome 1p32 and contains 12 
exons and 11 introns [114]. PCSK9 is initially synthesized as a 692-amino acid precursor (  
 75 kDa) which is composed of a signal peptide (aa 1–30), a prodomain (aa 31–152), a 
catalytic serine protease domain (aa 153–451) and a Cys- and His-rich C-terminal domain 
(CHRD; aa 452–692) [115]. PCSK9 zymogen shows an atypical activation pathway when 
compared with the 8 other members of PC family. After the cleavage of its signal peptide 
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in the ER, the zymogen proPCSK9 (aa 31–692) undergoes an autocatalytic intramolecular 
processing between Gln152 and Ser153, which is required for the release of the mature 
and active PCSK9 (   62 kDa) [3]. Indeed, has been recently described a mutation which 
prevents autocatalytic processing and PCSK9 secretion, associated with a 48% reduction 
in plasma LDL-C levels [116]. After cleavage, the prodomain remains tightly associated via 
hydrogen bonds to the catalytic site of the protein, preventing the access of other 
potential substrates to the catalytic pocket of PCSK9. Therefore the only known substrate 
of PCSK9 for proteolytic cleavage is itself and its activity is related to its binding to specific 
target proteins and to escort them toward intracellular degradation compartments [117] 
(Fig.6).  
 
 
 
Figure 6. Schematic representation of proprotein convertase subtilisin kexin 9 (PCSK9) zymogen  
processing [3]. 
 
 
The first PCSK9 target to be identified is the LDLR at the surface of hepatocytes. Secreted 
PCSK9 binds the epidermal growth factor-A (EGF-A) domain of the LDLR via its catalytic 
domain, as well as the analogous domain discovered in other LDLR superfamily members 
(very low density lipoprotein receptor [VLDLR], apolipoprotein E receptor 2 [ApoER2] 
[118], cluster of differentiation 36 [CD36] [119] and lipoprotein receptor–related protein 
1 [LRP1] [120]). Normally, the LDLR/LDL-C complex is internalized through clathrin heavy 
chain–coated vesicles and then proceeds to the endosomes,  where the acidic pH causes 
the dissociation of the LDLR and its recycling to the cell surface, whereas the LDL-C is 
directed to lysosomes for degradation [121]. Conversely, when secreted PSCK9 binds the 
LDLR, the complex does not dissociate at acidic pH, but is rather more tightly associated 
and it is escorted to lysosomes for degradation [122]. The majority of attention has been 
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focused on the interaction between secreted PCSK9 and the cell-surface LDLR. However, 
it is probable that beyond the extracellular pathway, PCSK9 can induce the degradation of 
the LDLR via an intracellular pathway. Indeed, some degradation of the LDLR precursor 
was observed following PCSK9 overexpression, showing that the LDLR might interact with 
PCSK9 before its O-linked glycosylation in the Golgi apparatus [123, 124]. The presence of 
two different pathways is supported by a recent observation which reveals that PCSK9 
lacking the M2 domain of the CHRD can still degrade the LDLR intracellularly but not 
when added outside cells. However, both the intracellular and the extracellular LDLR 
degradation activities of PCSK9 require the presence of the CHRD, necessary for the 
delivery of the PCSK9/LDLR complex to lysosomes. Whether these two pathways are 
functional in all tissues is still unknown [125] (Fig. 7). 
 
 
 
Figure 7. PCSK9-mediated degradation of LDLR. A complex of LDL-C, LDLR, and PCSK9 is internalized into 
hepatocytes into clathrin-coated pits and subsequently undergoes lysosomal degradation [126]. 
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4.2 Regulation of PCSK9 expression and plasma levels 
The regulation of PCSK9 expression is a quite complex process which, as it occurs with any 
other gene, begins at transcription. A tight scanning of the proximal promoter of the 
PCSK9 gene revealed that the promoter region carries a specificity protein 1 (Sp1) site, a 
hepatocyte nuclear factor 1α (HNF1α) site and two sterol-responsive elements (SREs) 
[127, 128]. Intracellular cholesterol content is the main factor that controls PCSK9 gene 
expression. SRE, the most conserved among the transcriptional motifs and the binding 
site for SRE-binding proteins (SREBPs), mediates the response of PCSK9 to cholesterol 
depletion, statins and SREBPs. PCSK9 expression is strongly downregulated by a high-
cholesterol diet in mice and upregulated in transgenic mice overexpressing nuclear 
SREBP-1a or SREBP-2 [127, 129]. Accordingly, Dubuc et al. demonstrated in vitro that 
statins, which inhibit HMGCoA reductase, the rate-limiting enzyme in cholesterol 
biosynthesis, resulting in a feedback activation of nuclear SREBP-2, increased the level of 
PCSK9 mRNA in HepG2 [128]. Moreover, SREBP-1c is involved in postprandial insulin 
upregulation of PCSK9 gene expression in primary mouse and rat hepatocytes,  as well as 
in vivo, during hyperinsulinemic-euglycemic clamp procedures performed on mice [130]. 
SREBPs activation of the PCSK9 gene promoter is enhanced by HNF1α, which binds to an 
element residing 28 bp upstream from SRE. Recently, Li et al. provided evidence 
suggesting that HNF1α site works cooperatively with SRE and that HNF1α mutation 
reduced PCSK9 promoter activity >90% in transfected HepG2 cells [131]. Upregulation of 
HNF1α expression by statins contributes to sustained PCSK9 production/secretion, which 
reduces the LDLR-mediated clearance of plasma LDL-C induced by these drugs, while its 
expression is downregulated by the natural hypocholesterolemic compound berberine 
[131, 132]. The PCSK9 promoter is also regulated by ligand-activated nuclear receptors, 
such as peroxisome proliferator–activated receptors (PPARs). Mice treated with the 
PPARα agonist fenofibrate show a 50% decrease expression of hepatic PCSK9, in a PPARα-
dependent manner [133], while in humans PCSK9 plasma levels are slightly (8.5%), but 
significantly, reduced in diabetic patients upon fenofibrate treatment, paralleling a 13% 
reduction in LDLC levels [134]. 
PCSK9 mature protein also undergoes post-transcriptional modifications. PCSK9 is 
susceptible to the proteolytic cleavage by other members of the PCs family, such as furin 
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and PC5/6A, which cleave the mature PCSK9 at Arg218, generating a truncated protein (  
 55 kDa). The activity of this truncated protein is discussed, but studies in cultured 
hepatocytes and in furin hepatic conditional KO mice suggest that furin-cleaved PCSK9 is 
inactive. The natural gain-of-function mutations R218S, F216L and D374Y, associated with 
hypercholesterolemia, result in total or partial loss of furin/PC5/6A processing [135]. 
However, Lipari et al. recently demonstrated that circulating furin-cleaved PCSK9 is able 
to regulate LDLR and serum cholesterol levels, although somewhat less efficiently than 
intact PCSK9 [136]. 
Overall, beyond transcriptional and post-transcriptional regulation, the key concept is 
that PCSK9 expression is mainly regulated by variation of cholesterol levels. Throughout 
the day and in response to fasting and cholesterol depletion, circulating PCSK9 displays 
significant variation, probably related to oscillations in hepatic cholesterol content and 
consequent modification in cholesterol biosynthesis [137]. As a consequence, PCSK9 
expression is consistently increased following cholesterol-lowering pharmacological 
treatments with agents such as statins [138], ezetimibe [139], or bile acid–binding resins 
[140]. In particular, statins induce SREBP-2 activity by inhibiting HMG-CoA reductase, 
which in turn increases hepatic LDLR expression and plasma LDL-C clearance. However, 
increased PCSK9 expression under these same conditions could attenuate statin efficacy 
by promoting LDLR degradation [141]. The effect of fibrates on circulating PCSK9 is still 
unclear, both reduced and increased PCSK9 levels were reported. Lambert and coworkers 
showed that plasma PCSK9 concentrations correlate with LDL-C and total cholesterol in 
diabetic patients and are decreased by fenofibrate treatment, while Costet et al. 
demonstrated that fenofibrate and atorvastatin increase circulating PCSK9 in diabetic 
patients, with no additive effect after 6 weeks of combined therapy [134, 142]. Finally, 
also the nutritional status and hormones such as glucagon, growth factor and sex 
hormones are surely involved in the regulation of PCSK9 plasma levels. Premenopausal 
women have higher PCSK9 levels when compared with men while in boys PCSK9 
decreases during puberty, although the mechanisms are still unclear [143, 144]. 
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4.3 PCSK9 targets beyond LDLR 
PCSK9 binds the extracellular domains of a highly selective subset of transmembrane 
receptors and escorts them to lysosomes for degradation, through a mechanism that is 
independent of its proteolytic activity. Although the LDLR is no doubt the main studied 
target of PCSK9, probably due to its physiological relevance in modulating the levels of 
circulating LDL-C, PCSK9 targets other receptor members of the LDLR superfamily [3]. This 
family consists of structurally closely related transmembrane proteins, among which 
VLDLR and ApoER2 are the closet to LDLR (59% and 46% identity, respectively). Poirier et 
al. demonstrated that PCSK9 in vitro affects, in an LDLR-independent manner, the levels 
of both VLDLR and ApoER2 and that the gain-of-function D374Y mutant is more active in 
enhancing the degradation of these receptors [118]. In vivo, endogenous PCSK9 
negatively regulates the levels of VLDLR in adipose tissue. The analysis of different mouse 
models reveals that this regulation is achieved by circulating, and not local, PCSK9. 
 Indeed, liver-specific PCSK9 KO mice show a dramatic increase in adipose VLDLR protein, 
while the expression of PCSK9 in the liver of PCSK9 KO mice reverts this phenotype [145]. 
More recently, has been discovered that PCSK9 enhances the degradation of LRP1 in 
mouse B16F1 melanoma cells and in chinese hamster ovary (CHO) cells, although proof of 
this activity in vivo is still lacking. However, the observation that the LDLR is not sensitive 
to PCSK9 in B16F1 cells suggests a distinct targeting mechanisms for these receptors 
[120]. CD36, a major receptor involved in transport of long-chain fatty acids 
and triglyceride storage, is also suspected to be a PCSK9 target in intestinal epithelial 
cells and adipose tissue. The overexpression of PCSK9 induces CD36 degradation and 
reduces the uptake of the palmitate analog Bodipy FL C16 and oxidized LDL in 3T3-L1 
adipocytes and hepatic HepG2 cells, respectively [119].  
Beyond transmembrane receptors, PCSK9 could improve the degradation of certain 
targets within the ER/ER-Golgi intermediate compartment, such as BACE1 (β-site amyloid 
precursor protein (APP)-cleaving enzyme 1) and ENaC (epithelial Na+ channel). BACE1 is 
transiently acetylated in the lumen of the ER/ER-Golgi intermediate compartment. The 
acetylated protein is able to reach the Golgi apparatus, while the nonacetylated one is 
retained and degraded in a post-ER compartment. PCSK9 contributes to the disposal of 
nonacetylated BACE1, enhancing the generation of amyloid β-peptide (Aβ) [146]. 
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Moreover, within the ER/ER-Golgi intermediate compartment of epithelial cells of the 
renal collecting duct, PCSK9 induces the degradation of the ENaC, that is critical for 
Na+ homeostasis and blood pressure control [147].  
 
4.4 Role of PCSK9 in extrahepatic tissues 
Several experimental studies clearly show that the liver is simultaneously the key organ 
modulating PCSK9 plasma levels and the main target of PCSK9 activity, where it is 
involved in the binding and degradation of LDLR. However, PCSK9 is expressed in many 
extrahepatic tissues and organs, where it plays additional functions [1] (Fig. 8).  
 
 
Figure 8. Extrahepatic targets of PCSK9 besides liver [1]. 
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4.4.1 Brain 
Despite PCSK9 was originally discovered in brain (NARC-1), its role in this tissue is  still 
debate, with evidence of both pro-apoptotic effects and protective activities in the 
development of the nervous system. PCSK9 is highly expressed in cells with a significant 
proliferative index, including the embryonic brain telencephalon and cerebellum 
neurons, which present a higher recruitment rate of undifferentiated neural progenitor 
cells, when transfected to overexpress PCSK9 [148]. PCSK9 and LDLR are co-expressed in 
the telencephalon and cerebellum during active neurogenesis and in the rostral extension 
of the olfactory peduncle (RE-OP) of adult animals. Although the levels of LDLR are similar 
in the adult brain of PCSK9 KO and WT mice, PCSK9 is able to downregulate LDLR 
expression during brain development and following transient ischemic stroke. Of note, 
following experimental transient ischemic stroke in mice, PCSK9 is not expressed in the 
infarct and penumbra areas (suggesting that it may not play a role in cell death) but 
rather in the area where neurogenesis takes place [149]. Anyway, PCSK9 KO mice are 
viable, without any relevant alterations in the cerebellum, hippocampus or 
cortex, according to the observation that humans carrying complete LOF mutations of 
PCSK9 show no major neurological defects [150].  
Cholesterol plays a key role in neuronal development as well as in brain function, and the 
reduction of plasma cholesterol levels to a large extent might negatively impact brain 
function. On the contrary, hypercholesterolaemia is considered an important risk factor 
for neurodegenerative diseases such as Alzheimer’s disease (AD), and lipid-lowering 
therapies can reduce the risk to develop these pathological conditions. BACE1 (β-site 
amyloid precursor protein (APP)-cleaving enzyme 1) is the β-secretase enzyme required 
for the production of the neurotoxic β-amyloid (Aβ) peptide, which have a crucial early 
role in the etiology of AD. In vitro, PCSK9 overexpression leads to a reduction in 
endogenous BACE1 levels, whereas the down-regulation of PCSK9 by siRNA completely 
normalized the levels of BACE1.  In vivo, PCSK9 KO mice showed higher levels of BACE1 
and Aß in the neocortex, suggesting that in the brain PCSK9 is able to regulate the 
metabolism of BACE1 and the rate of Aß production [146]. However, in randomized 
clinical trials the treatment with PCSK9 mAbs is not associated with increased incidence of 
neurocognitive adverse events, as well as in PCSK9 LOF carriers [151-153]. 
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Finally, PCSK9 has been identified to be up-regulated during apoptosis induced by 
withdrawal of potassium and serum in cultured cerebellar granule neurons (CGN). The 
transient overexpression of recombinant PCSK9 in CGNs is pro-apoptotic and only 
partially sensitive to caspase inhibitors, thus defining both a caspase-dependent and a 
caspase-independent component of PCSK9 pro-apoptotic effect [154]. On the contrary, 
PCSK9 overexpression promoted cell proliferation in a model of human 
neuroglioma, suggesting an anti-apoptotic effects in these cells [155]. Therefore, even if 
PCSK9 inhibitors are already used in the clinic for controlling plasma lipids, we are far 
from fully understanding the physiological role of this protein.  
4.4.2 Pancreas 
The link between PCSK9 and metabolic dysfunction goes beyond the modulation of the 
VLDLR in adipocytes, since PCSK9 is detectable also in mouse and human isolated 
pancreatic islets. Immunohistochemistry analysis showed that PCSK9 co-localizes 
specifically with somatostatin in human pancreatic δ-cells, while α- and β-cells apparently 
do not secrete detectable levels of PCSK9, although they respond to exogenously added 
PCSK9 [156]. Moreover, the LDLR is abundantly expressed in pancreatic β-cells in humans, 
mice and rats, where it plays a pivotal role in the uptake of plasma LDL [2, 157]. 
Cholesterol homeostasis is crucial for β-cells function and survival and excessive 
cholesterol accumulation causes a significant reduction in islets’ ability to secrete insulin 
in response to glucose [108]. All these findings support the investigation of a possible 
involvement of PCSK9 in glucose homeostasis. 
Mbikay and co-workers proved that old male PCSK9 KO mice express more LDLR in 
pancreatic islet cells, when compared with controls. The increased LDLR expression is 
paralleled with morphological abnormalities of pancreatic islets, although it is not clear 
whether this phenotype is correlated with impaired insulin secretion [158]. Indeed, 
contradictory results have been obtained in two different studies: one shows no effect of 
PCSK9 on insulin secretion and glucose tolerance [156],  while the other reveals 
that PCSK9 KO mice are hypoinsulinaemic, hyperglycaemic and intolerant to glucose. In 
the latter study, PCSK9 KO islets present signs of malformation, apoptosis and 
inflammation [158]. These discrepancies are probably age dependent (8–10 weeks  vs 4–5 
months) and  strain dependent (mice with different genetic background). However, as the 
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LDLR-cholesterol axis has been suggested to play a crucial role in modulating β-cell 
function and insulin secretion, a potential physiological role of PCSK9 in the pancreas 
cannot be excluded. 
Also in humans data from carriers of PCSK9 LOF mutations, which present undetectable 
or very low levels of the circulating protein, are discordant. Some studies report no 
pancreatic dysfunction or increased incidence of diabetes in carriers compared to 
controls [153, 159], while others link PCSK9 LOF to an increased incidence of diabetes. 
The FH individuals carrying the PCSK9 InsLEU genetic variant (LOF) seem to be protected 
from major cardiovascular events but show increased occurrence of prediabetes and 
diabetes status [160].  In the cohort of the Dallas Heart Study, it has been shown a 
significant correlation among PCSK9 levels and fasting serum glucose, insulin and HOMA-
IR [143], confirming the data obtained both in healthy volunteers and in a cohort of 
children [161, 162]. Moreover, Yang et al. established a positive correlation between 
PCSK9 levels and hemoglobin (Hb)A1c in T2DM patients, while not in patients without 
[163]. Interestingly, a genetic score consisting of independently inherited polymorphisms 
in the PCSK9 gene in more than 110.000 subjects, although resulting into reduced LDL‐C 
levels and cardiovascular events, associates to increased risk of diabetes [164, 165]. 
Conversely, patients with familial hypercholesterolemia (decreased LDLR function) appear 
to have a lower risk of diabetes [166] (Fig. 9).  
Regarding the clinical evidences, the effect of Alirocumab on the onset of new cases of 
diabetes has been evaluated in the ODYSSEY LONG TERM trial. No significant difference 
has been reported between the Alirocumab and placebo arms after a follow-up of 
78 weeks [112]. In the OSLER-1 and OSLER-2 studies, conducted with Evolocumab, no 
measurable effects on glycemic parameters, including fasting plasma glucose, HbA1c and 
new-onset diabetes, have been showed after one year of treatment [167]. However, 
despite no evidence of PCSK9 inhibition effect on glucose metabolism, longer period and 
larger population could be necessary in order to reveal possible side effects. Indeed, the 
increased of T2DM observed with the use of statins was appreciated only after the 
analysis of several prospective and retrospective clinical trials.   
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Figure 9. Association of Low-Density Lipoprotein Cholesterol (LDL-C)–Lowering Genetic Variants With 
Coronary Artery Disease and Type 2 Diabetes [165] 
 
4.4.3 Vascular tissue 
Beyond the extensively studied role of PCSK9 in liver, recent evidences report that PCSK9 
is also present in human carotid atherosclerotic lesions. Among the cells of the artery 
wall, smooth muscle cells (SMCs) express significant levels of PCSK9, while its expression 
in endothelium cells (ECs) and macrophages is still debated [4]. The vascular expression of 
PCSK9 is notable higher in regions with low shear stress and is coupled with reactive 
oxygen species (ROS) production and inflammation [168].  
In vascular SMCs PCSK9 is processed and released through a mechanism similar to the 
one described in hepatocytes. PCSK9 derived from SMCs  is functionally active and 
capable of reducing LDLR expression at the surface of arterial macrophages, modulating 
the LDL accumulation in the artery wall. This finding suggests a possible role for PCSK9 in 
oxidized LDL (oxLDL) and foam cell formation and in atherogenesis, directly affecting the 
function of vascular cells [169]. Notably, siRNA directed against PCSK9 attenuates OxLDL-
dependent apoptosis in endothelial cells, while OxLDL are able to induce the expression 
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of PCSK9 in these cells [170]. Denis et al. investigated the role of PCSK9 and LDLR on 
the atherosclerotic process in vivo, using WT, apoE KO and LDLR KO mouse models. They 
showed that PCSK9 deficiency ameliorates atherosclerosis in apoE KO mice by improving 
their lipid profile, but not in LDLR KO mice, proposing that the observed effect is 
dependent on the increased levels of LDLR in PCSK9 KO/apoE KO mice [171]. Moreover, 
two recent studies reported an association between serum PCSK9 levels and carotid 
intima media thickness (IMT), a surrogate marker of preclinical atherosclerosis, both in 
hypertensive and in FH patients. This correlation occurs independently of the plasma lipid 
profile and suggests that circulating PCSK9 may have an important role in early 
pathogenesis of the disease [172, 173]. Whether PCSK9 is expressed by macrophages is 
currently a subject of discussion. Murine J774A macrophages do not express PCSK9 
[169], whereas Giunzioni and colleagues demonstrated that murine peritoneal 
macrophages secrete functional PCSK9 [174].  
Anyway, systemic and local PCSK9 (by SMCs or macrophages) affects macrophages LDLR 
expression, while the absence of the LDLR mitigates the negative effect of PCSK9 on 
atherosclerosis and inflammation. Currently there are no studies that elucidate the 
potential role of PCSK9 in heart function. PCSK9 could indirectly affect cardiomyocytes by 
modulating the plasma concentrations of LDL-C and oxLDL, which effects on 
cardiomyocytes are less well reviewed as those to vascular cells [175]. 
4.4.4 Small intestine 
Despite notable levels of PCSK9 mRNA are detectable in the small intestine and the 
intestine is a key player in maintaining cholesterol balance, the knowledge of the role of 
PCSK9 in this tissue is still partial. PCSK9 is highly expressed both in rat and mouse 
embryos and adult ileum and jejunum [148, 176], while in humans immunohistochemical 
analysis reveal that PCSK9 is present almost exclusively in the epithelial barrier of the 
duodenum and ileum, both in enterocytes and goblet cells [177].  Interestingly,  Levy and 
coworkers have recently shown that in Caco-2/15 cells PCSK9 is secreted from basolateral 
site to the culture medium, suggesting that PCSK9 synthesized by the enterocytes may be 
released in the circulation [178].  
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As it occurs in liver, PCSK9 is able to trigger the degradation of the LDLR expressed at the 
basolateral surface of the enterocytes, modulating cholesterol homeostasis and 
chylomicron metabolism. Indeed, Caco-2/15 cells treated with exogenous PCSK9 show 
reduced levels of the LDLR on the basolateral membrane paralleled with increased 
cholesterol uptake and apoB48 synthesis and output [178]. The positive correlation 
between PCSK9 levels and apoB48 secretion observed in Caco-2/15 cells has been 
confirmed in in vivo studies. PCSK9 KO mice exhibit a significantly decreased postprandial 
triglyceridemia after olive oil gavage, caused by reduced lymphatic apoB48 and TG-rich 
lipoproteins output  and by increased capacity to clear chylomicrons from the blood 
[177]. Although the LDLR is involved in this process, the chylomicrons clearence rate 
probably requires the ability of PCSK9 to target other receptors, such as the VLDLR and 
apoER2 [118].  
The involvement of PCSK9 in the postprandial response was also investigated in humans, 
where Cariou et al. pointed out that heterozygous PCSK9 missense mutations may 
associate with profound hypobetalipoproteinemia. [179]. In addition, PCSK9 seems to 
affect intestinal cholesterol absorption. The addition of exogenous PCSK9 to cultured 
enterocytes reduce LDLR expression and cholesterol uptake from the basolateral media.  
Under these conditions, cholesterol uptake through the apical membrane is increased via 
the upregulation of cholesterol transporters (NPC1L1, CD36) [178].  
4.4.5 Adipose tissue 
Although PCSK9 is a key modulator of hepatic LDLR and circulating LDL-C levels, its 
involvement in the regulation of adipogenesis requires further investigation. In addition 
to the LDLR, PCSK9 is able to target other receptors of the LDLR superfamily, such as the 
VLDLR and ApoER2 [118]. The VLDLR, highly expressed on the adipocytes surface, plays a 
key role in the hydrolysis of triglyceride-rich lipoproteins, a critical step for fat storage in 
this tissue.  
Interestingly, despite adipocytes do not express PCSK9, circulating PCSK9 negatively 
regulates the levels of VLDLR in adipose tissue. Indeed,  together with a lower 
postprandial triglyceride levels, PCSK9 KO mice present adipocyte hypertrophy and a 
significant increased visceral adiposity. In particular, a detailed analysis demonstrated 
 Introduction 
49 
 
that PCSK9 KO mice are characterized by a larger perigonadal (+70%) and perirenal 
(+90%) depots compared to WT littermates. Of note, this phenotype was demonstrated 
to be independent by the LDLR expression but rather to be mediated by the VLDLR and 
CD36 modulation [119, 145]. In humans, although a modest positive correlation between 
circulating PCSK9 levels and the BMI has been reported [143], specific studies aimed at 
analyzing the association between plasma PCSK9 and obesity are necessary to clarify the 
role of PCSK9 in adipogenesis. Interestingly, the levels of resistin, an adipose tissue 
derived adipokine, is inversely correlated with circulating PCSK9 in lean, but not obese, 
subjects, thus raising questions about the physiological relevance of resistin in the control 
of PCSK9 in vivo [180].  
4.4.6 Kidney and adrenals 
PCSK9 is abundantly expressed in renal tissues, but surprisingly it only marginally 
interferes with kidney and adrenals LDLR expression. This might be due to a lower local 
concentration of PCSK9 or to a different expression of cofactors necessary for PCSK9-
dependent LDLR degradation. Adrenals are enriched in annexin A2, a natural endogenous 
inhibitor of PCSK9, which could prevent its function on the LDLR. Indeed, Anxa2-KO mice 
present double PCSK9 plasma levels and LDLR reduction by ≈50% in some extrahepatic 
tissues, such as adrenals and small intestine but not in liver [181]. Another possibility is 
that the extrahepatic tissues, which do not respond to PCSK9, are unable to sort 
efficiently the PCSK9/LDLR complex to lysosomes, as recently shown in fibroblasts [182].  
Nevertheless these tissues express reasonable amount of PCSK9, recommending a 
possible additional functions of PCSK9 beyond the regulation of LDLR expression and 
cholesterol homeostasis. The epithelial Na+  channel (ENaC) was lately identified as a 
PCSK9 target in the collecting duct of the kidney. PCSK9 regulates ENaC trafficking and cell 
surface expression through its ER degradation, suggesting that reductions in PCSK9 might 
result in increased Na+  renal absorption and increased risk of hypertension [147]. 
However, subjects carrying LOF mutations of PCSK9 do not exhibit increased prevalence 
of hypertension compared with non-carriers [183] and in studies with anti-PCSK9 mAbs 
no effect on blood pressure has been reported to date [152, 184]. Many studies have 
recently proposed a role for PCSK9 in the development of dyslipidaemia in renal 
pathologies. Subjects with renal failure and proteinuria present significant increased 
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PCSK9 plasma levels compared with matched healthy individuals [185], as well as patients 
with nephrotic syndrome. These subjects show elevated LDL-C levels, with a significant 
direct correlation with plasma PCSK9 concentrations, suggesting that increased PCSK9 can 
cause LDLR deficiency, which in turn contributes to the onset of hypercholesterolaemia 
[186]. Despite the physiological role of PCSK9 in kidney and adrenals is still not clear and it 
requires further investigation, these findings indicate that PCSK9 inhibition could be a 
therapeutic strategy for improving dyslipidemia associated with chronic kidney disease.  
 
4.5 PCSK9-based therapy 
After its discovery in 2003, PCSK9 was rapidly recognized as a key player in LDL 
metabolism, because of its ability to prevent the recycling of the LDLR to the hepatocytes 
surface. The crucial role of PCSK9 in lipid metabolism was disclosed performing genetic 
studies, which revealed a strong association between PCSK9 variants and alterations in 
cholesterol levels. GOF mutations in PCSK9 were identified to be involved in FH [187], 
while a range of LOF mutations resulted in reduced LDL-C levels and concomitant 
decreased risk of cardiovascular events [188]. Moreover, preclinical studies showed that 
statin-mediated LDL-C reduction, which occurs through increased LDLR expression on 
hepatocytes along with increased LDL turnover, is associated with induced PCSK9 
expression. This increased expression and secretion of PCSK9 with statin therapy 
attenuates, at least in part, the LDL-lowering efficacy of statins and also of ezetimibe 
[128]. These observations suggest that PCSK9 inhibition may represent a promising 
therapeutic target for LDL-C lowering, also in statin-treated patients. 
Since PCSK9 acts both intracellularly as a chaperone targeting the LDLR to the lysosomes 
and extracellularly by promoting LDLR internalization [189], the inhibition of both its 
synthesis and its interaction with the LDLR represents an attractive approach to obtain a 
lipid-lowering effect. The interaction between PCSK9 and the LDLR can be diminished by 
removing PCSK9 from the circulation (monoclonal antibodies and vaccines) or proposing 
alternative binding partners rather than LDLR (mimetic peptides or adnectins). 
Alternatively, the inhibition of PCSK9 can be performed at the expression level 
(CRISPR/Cas9 system, berberine, silencing RNA and oligonucleotides) [175]. To date the 
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best approach is related to the use of a monoclonal antibodies (mAb) against PCSK9, that 
block its binding to the LDLR via an allosteric mechanism. Thanks to the advance 
production technologies, it is now possible to generate humanized (bococizumab, 
LY3015014) or fully human (Evolocumab, Alirocumab) antibodies with a significant 
reduced immunogenicity compared with the antibodies of the early-generation [190] (Fig. 
10). 
 
 
Figure 10. Metabolism of lipoproteins when therapies that target proprotein convertase subtilisin/kexin 
type 9 (PCSK9) are used [191]. 
 
 
4.5.1 CRISPR/Cas9 platform 
The CRISPR/Cas system, found in approximately 40% of sequenced bacterial genomes, is 
an adaptive immune system that awards resistance against the invasion of foreign nucleic 
acids, including viruses and plasmids. Recently, a simple version of the CRISPR/Cas 
system, CRISPR/Cas9, has been modified to edit genomes. It includes a synthetic guide 
RNA (gRNA) linked to the Cas9, which delivers the complex to the cellular genome that 
can be cut at a desired location, removing the existing genes and/or adding new ones 
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[192]. Ding et al., using the CRISPR/Cas9 system to target PCSK9 in mouse liver, 
demonstrated that after the administration of the virus, the mutagenesis rate of PCSK9 in 
the liver is higher than 50%. This results in increased hepatic LDLR expression, decreased 
plasma PCSK9 levels and decreased plasma cholesterol levels (by 35-40%) [193]. In a 
study using FRG KO mice, which have chimeric-humanized liver, the treatment with 
CRISPR/Cas9 system to target the human PCSK9 gene induces a significant down-
regulation of PCSK9 both in liver and in the circulation. This technique reveals an high on-
target mutagenesis (around 50%) with a minimal off-target mutagenesis, yields important 
information on the efficacy and safety of CRISPR-Cas9 therapy [194]. Although the 
CRISPR/Cas9 platform targeting PCSK9, causing a permanent PCSK9 alteration, is a 
promising genome editing technology, many questions remain unresolved.  
4.5.2 Antisense oligonucleotides (ASOs) 
Antisense oligonucleotides (ASOs) are short, single-stranded, synthetic nucleotide 
sequences designed to specifically bind to a target messenger RNA (mRNA). This binding  
induces a selective degradation of the mRNA or prevents the translation of the selected 
mRNA into protein.  ASOs are successfully deliver  to the hepatic nucleus and have the 
ability to inhibit unique targets with high specificity [195]. Preclinical trials revealed that 
the administration of a second generation PCSK9 ASO (ISIS 394814) to high fat-fed mice 
for 6 weeks reduces total cholesterol and LDL-C by 53% and 38%, respectively, and the 
levels of PCSK9 mRNA by 92%. The inhibition of PCSK9 expression is associated with a 2-
fold increase in hepatic LDLR protein levels [196].  Antisense oligonucleotides that contain 
at least one locked nucleic acid (LNA) present a higher binding affinity and specificity to 
mRNA. LNA ASOs reduce the mRNA and protein levels of PCSK9, with a concomitant 
increase in LDLR protein levels, both in cell lines (HepG2 and HuH7 cells) and mouse liver. 
In particular, the intravenous administration of LNA ASOs in mice leads to a significant 
reduction in PCSK9 mRNA levels (-60%). This effect lasts more than 16 days, as well as the 
twofold up-regulation of the hepatic LDLR protein levels [197]. Also when translated in 
non-human primates, this technology (LNA SPC5001 and LNA SPC4061) produces a very 
long lasting reduction of LDL-C, paralleled with an important decrease of both PCSK9 
mRNA and protein levels [198]. Although the promising preclinical data, the first phase I 
clinical trials in healthy human subjects and individuals with FH were terminated early 
 Introduction 
53 
 
(NCT01350960). SPC5001 was seen to cause mild to moderate injection site reactions and 
renal tubular toxicity. Kidney biopsy revealed multifocal tubular necrosis and signs of LAN 
accumulation, a damage reversible upon termination of SPC5001 treatment [199, 200]. 
Further development of SPC4061 was discontinued for undisclosed reasons. Therefore, 
even if ASOs present high affinity and specificity, the high production cost, the undesired 
side effects and the required routes for intravenous or subcutaneous administration limit 
its use in individuals with hyperlipidemia.  
4.5.3 Small interfering RNA (siRNA) 
Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, 20-25 base 
pairs long, that interfere with the expression of specific genes with complementary 
nucleotide sequences, leading to the degradation of the mRNA after 
transcription, resulting in no translation. Delivery systems based on liposomes and lipid 
nanoparticles (LNPs) are the most commonly used nonviral vectors for siRNA delivery, 
both in academic studies and clinical trials [201]. Studies in mice and rats have reported 
that liver-specific siRNA silencing of PCSK9 is able to decrease the PCSK9 mRNA levels by 
50–70% and the plasma LDL-C concentrations by 60%. Also in transgenic mice expressing 
human PCSK9, siRNAs silence the human PCSK9 transcript by >70%, with a significant 
reduction of  the plasma protein levels. In nonhuman primates, siRNA mediated 
knockdown of PCSK9 is rapid, substained and reversible and lasts for 3 weeks after a 
single intravenous administration. The reduced levels of circulating PCSK9 is paralleled 
with a decrease in apoB and LDL-C, without measurable effects on either HDL-C or TGs 
[202]. In humans, Fitzgerald and coworkers investigated the safety and efficacy of siRNA 
ALN-PCS, administered intravenously in healthy subjects with raised cholesterol who 
were not on lipid-lowering treatment. They showed a dose-dependent reduction in 
plasma PCSK9 and LDL-C levels, with the highest dose (0.4 mg/kg) conferring 70% and 
40% reductions in PCSK9 and LDL-C levels respectively. ALN-PCS has a long lasting effect, 
sustained for 2–3 weeks after a single administration, and overall is well tolerated with 
side effects being similar to placebo [203]. More recently, has been tested the 
subcutaneous administered of ALN-PCS, both in single and multiple doses, in healthy 
volunteers with an LDL-C level of at least 100 mg/dl. In this phase I trial, no severe side 
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effects were observed and the doses of 300 mg or more (in single or multiple doses) is 
enough to reduce the levels of PCSK9 and LDL-C for at least 6 months [204]. 
4.5.4  Berberine and oleanolic acid 
Despite small molecules have received considerable attention because of their low cost,  
the efforts to develop small-molecule inhibitors of PCSK9 have often been 
unsuccessful. However, other small molecules which directly inhibit PCSK9 expression, 
such as berberine and oleanolic acid, seem to be promising [205]. Berberine (BBR), usually 
found in the roots, rhizomes, stems and bark of several plants,  is a quaternary 
ammonium salt from the protoberberine group of isoquinoline alkaloids. BBR is endowed 
with several pharmacological activities, including anti-microbial, glucose and cholesterol-
lowering, anti-tumoral and immunomodulatory properties. BBR exerts its protective role 
in atherosclerosis increasing hepatic LDLR expression, due to increased LDLR mRNA 
stability, with a higher LDL uptake in BBR-treated cells [206]. While statins increase the 
expression of hepatic PCSK9, BBR has been shown to reduce PCSK9 mRNA and protein 
levels in HepG2 cells, in a time and dose dependent manner. This effect is not due to 
changes in the PCSK9 mRNA stability but most likely to an impaired transcription of 
the PCSK9 gene [207]. Indeed, BBR reduces the cellular levels of both hepatocytes nuclear 
factor 1α (HNF1α) and sterol regulatory element-binding protein 2 (SREBP2), which co-
regulate the transcription of PCSK9. Although SREBP2 plays a key role also in LDLR 
transcription, it is not altered by the treatment with BBR, suggesting that the overall 
effect of BBR is in favor of the LDLR expression [131]. Recently, studies in mice and 
hamsters revealed that the administration of BBR to hyperlipidemic animals decreases 
both hepatic PCSK9 mRNA levels (-46%) and circulating PCSK9 concentrations (-50%), 
while significantly increases the LDLR protein in liver (+67%). Interestingly, 
hepatic HNF1α protein levels result markedly reduced after the BBR treatment, while no 
difference in HNF1α gene expression, suggesting a mechanism linked with an 
accelerated degradation of the protein [208].  
Oleanolic acid (OA), widely distributed in food and plants, is a naturally occurring 
pentacyclic triterpenoid related to betulinic acid. OA presents several beneficial 
properties, such as antioxidative, anti-cancer, hepatoprotective, anti-inflammatory, 
hypolipidemic and anti-atherosclerotic effects [209, 210]. In db/db mice, the treatment 
 Introduction 
55 
 
with OA improves lipid and lipoprotein metabolism, reducing serum TG, LDL-C, free fatty 
acids and hepatic lipid accumulation, while increasing circulating HDL-C. In vitro, OA 
decreases the levels of PCSK9 protein and mRNA in HepG2 cells, in a time and dose 
dependent manner. However, the underlying mechanism is still unknown and the OA 
efficiency is limited because of its low bioavailability and insolubility in water [205]. 
4.5.5 Anti-PCSK9 monoclonal antibodies (mAbs) 
Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal 
antibodies (mAbs) to specifically target certain cells or proteins. Therapeutic mAbs act 
through several mechanisms, such as blocking the activity of targeted molecules, 
inducing apoptosis in cells which express the target or modulating signalling pathways. 
Currently, PCSK9 mAbs, that bind to PCSK9 and allow the LDLR to recycle to its higher 
potential, represent the most advanced and promising class of PCSK9 inhibitors. Two 
fully-human PCSK9 mAbs, Alirocumab and Evolocumab, were approved by the FDA (US 
Food and Drug Administration) and the EMA (European Medicines Agency) in 2015. The 
humanized PCSK9 mAb Bococizumab was discontinued from further clinical development 
due to increased immunogenicity and limited LDL-C lowering in 2016. Actually, a third 
humanized PCSK9 mAb, LY3015014, is under development [211].  
Alirocumab 
Alirocumab (REGN727/SAR236553), which is marketed by Sanofi/Regeneron under the 
brand name Praluent, was studied both in phase I and phase II trials. The phase I trials 
revealed that Alirocumab is able to reduce, in healthy volunteers, LDL-C in a dose-
dependent way (-65% at maximal doses), both after an intravenous and subcutaneous 
administration. In non-FH patients on atorvastatin and LDL > 100 mg/dL or with LDL > 130 
mg/dL being managed by diet alone, Alirocumab reduces LDL-C up to 65% and up to 60% 
respectively [212]. The phase II trials, which studied the efficacy of Alirocumab in patients 
with FH, showed that the most efficacious regimen of 150 mg every 2 weeks (Q2W) 
reduces LDL-C up to 70%, paralleled with a significant reduction in apoB levels and 
increased HDL-C. Interestingly, in patients on statin therapy, the Alirocumab mediated 
LDL-C reduction is independent from different doses of atorvastatin (10 mg vs 80 mg) 
[213, 214].  
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The phase III randomized, double-blinded ODYSSEY trials were designed to evaluate 
Alirocumab for long-term safety, efficacy and adverse events and include data from 
different open label studies. CHOICE I trial was designed to evaluate Alirocumab in 
patients with poorly controlled hypercholesterolemia and showed that Alirocumab 
(300 mg every 4 weeks; Q4W) significantly reduces LDL-C both in statin-naive patients (-
52%) and in patients on maximally tolerated statins (-59%), when compared to placebo. 
Similarly, COMBO I and II trials studied the effect of Alirocumab treatment in patients 
with LDL-C > 70 mg/dL and high cardiovascular risk on maximally tolerated statin therapy. 
COMBO I (316 patients) demonstrated that Alirocumab (75 mg Q2W, increased to 150 mg 
Q2W at week 12 if at week 8 LDL-C was ≥70 mg/dL) reduces LDL-C up to 50% after 24 
weeks of treatment, compared to placebo. COMBO II (720 patients), comparing Ezetimibe 
(10 mg/die) to Alirocumab (75 mg Q2W) in patients on background statin therapy, 
showed that Alirocumab induces a 50% LDL-C reduction vs 20% reduction with ezetimibe 
at 24 weeks [215]. OPTIONS I trial randomized 355 patients with hypercholesterolemia 
and LDL > 70 mg/dL and found that the addition of Alirocumab (75 mg Q2W increased to 
150 mg Q2W) to atorvastatin  (20 mg/die or 40 mg/die) produced the greatest reduction 
in LDL-C as compared to addition of ezetimibe, doubling atorvastatin dose or switching to 
rosuvastatin [216]. OPTIONS II trial studied the association between Alirocumab and 
rosuvastatin using a similar protocol and obtaining results comparable with those 
obtained in OPTIONS I [184]. CHOICE II and ODYSSEY ALTERNATIVE evaluated Alirocumab 
in patients intolerant to statin therapy. In CHOICE II trial 241 patients with a history of 
statin intolerance demonstrated a 56% reduction in LDL-C when treated with Alirocumab 
(150 mg Q4W), while the ODYSSEY ALTERNATIVE trial (314 patients) showed a 45% 
reduction in LDL-C with Alirocumab (75 mg Q2W) as opposed to 15% reduction in LDL-C 
with ezetimibe (10 mg/die), at 24 weeks [217]. FH I and FH II trials were designed to 
evaluate a total of 735 patients (486 and 249, respectively) with heterozygous FH, 
insufficiently controlled on lipid lowering therapy. These trials showed that Alirocumab 
(75 mg Q2W, increased to 150 mg Q2W at 12 week if at week 8 LDL-C was ≥70 mg/dL) is 
able to reduce LDL-C levels by 48.8% (FH I study) and  by 48.7% (FH II study), compared to 
placebo [218].  Finally, ODYSSEY LONG TERM trial, which was recently 
published, evaluated 2341 patients with hyperlipidemia on maximally tolerated statins 
and high risk for coronary heart disease (CHD). The patients treated with 150 mg 
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Alirocumab Q2W showed lower LDL-C by 62% at 24 weeks, compared to placebo. These 
results persisted at 78 weeks and the reduction in LDL-C appeared to be associated with 
reduction in the combined end-point of death from CHD, nonfatal MI, fatal or nonfatal 
ischemic stroke or unstable angina [112]. The ODYSSEY Outcomes trial (NCT01663402) is 
still ongoing and will assess the effects of Alirocumab on cardiovascular events in 18000 
patients on maximally tolerated statin therapy, with results expected in February 2018 
[219]. 
The side effects of Alirocumab have been evaluated on 2476 patients, that participate to 
the clinical trials mentioned above. The most common adverse effects observed with 
Alirocumab include nasopharyngitis, injection site reactions (erythema, itchiness, 
swelling, pain or tenderness), influenza, sinusitis, bronchitis, urinary tract infection, 
myalgia and muscle spasms. Alirocumab is contraindicated in patients who develop 
serious hypersensitivity reactions such as hypersensitivity vasculitis or allergic reactions, 
which require hospitalization. Among these adverse effects, the most common causes 
that lead to drug discontinuation are allergic reactions and elevated liver enzymes [219]. 
Evolocumab 
Evolocumab (AMG 145), marketed by Amgen under the brand name Repatha, is a fully 
human monoclonal antibody inhibiting PCSK9. It has a molecular weight of 144 kDa and is 
usually administered by subcutaneous injection at a dose of 140 mg Q2W or 420 mg Q4W 
[205]. The phase I trials demonstrated that in healthy volunteers Evolocumab, 
administered both subcutaneously and intravenously, leads to a short-term dose-
dependent reduction in LDL-C by up to 75% with a maximally dose of 420 mg, compared 
to placebo. Similar results were obtained in hypercholesterolemic statin-treated subjects, 
including those with heterozygous FH or taking the highest doses of atorvastatin or 
rosuvastatin. No serious adverse events occurred [220]. The phase II trials were 
subsequently performed to show the benefits of Evolocumab in LDL-C lowering when 
added to maximally tolerated statin therapy in patients with hypercholesterolemia 
(including FH). In LAPLACE-TIMI57 trial, 631 patients on stable statin therapy and LDL-C > 
85 mg/dL were treated with Evolocumab 70 to 140 mg Q2W or 280 to 420 mg Q4W, 
obtaining an LDL-C reduction up to 65% and up to 50%, respectively [221]. The MENDEL 
trial studied Evolocumab, used as monotherapy, in 406 patients with 
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hypercholesterolemia. The optimal frequency of Evolocumab therapy was shown to be 
twice monthly to determine a 50% to 60% reduction in LDL-C, when combined with 
statins. However, when used as a monotherapy, also a frequency of one administration 
Q4W would be acceptable [222]. 
Evolocumab was subsequently evaluated in PROFICIO phase III program, which includes 
14 trials performed in different populations. In LAPLACE-2 study, 1899 patients with 
fasting hyperlipidemia were randomized to a daily moderate or high intensity statin 
regimen and after 4 weeks further randomized to receive Evolocumab (140 mg Q2W or 
420 mg Q4W) or placebo. After 12 weeks of treatment, Evolocumab reduces LDL-C levels 
by 75% (both on Q2W and Q4W regimen), when compared to placebo, both in moderate 
and high intensity statin groups [223]. MENDEL-2 trial compared the efficacy of biweekly 
(140mg) and monthly (420mg) Evolocumab with placebo and oral ezetimibe in 614 
patients with fasting LDL-C ≥100 mg/dL and <190 mg/dL and low risk on Framingham 
scale (≤ 10%). Evolocumab treatment is able to reduce LDL-C by up to 57% more than 
placebo and 40% more than ezetimibe [151]. GAUSS-2 trial was designed to evaluate the 
efficacy and safety of subcutaneous Evolocumab compared to oral ezetimibe in 
hypercholesterolemic patients who are statin intolerant, predominantly due to muscle-
related side effects. In this 12-week double-blind study, 307 patients were treated with 
Evolocumab (140 mg Q2W or 420 mg Q4W) and compared to daily oral or subcutaneous 
placebo (both placebo groups on 10mg ezetimibe). At 12 week, Evolocumab group 
showed a reduction in LDL-C by 56% vs 39% in the other groups (placebo + ezetimibe 
arm) [224]. Similarly, GAUSS-3 trial assessed the efficacy of Evolocumab in 218 statin 
intolerant patients, enrolled after an initial phase of the study which included 
administration of atorvastatin (20 mg) for 10 weeks vs placebo. The patients who 
experienced muscle related adverse effects received Evolocumab (420 mg Q4W, divided 
in 3 doses) vs ezetimibe (10 mg/die). After 24 weeks, LDL-C was reduced by 53% with 
Evolocumab compared to 17% with ezetimibe, with no difference in muscle related side 
effects [225]. DESCARTES trial evaluated 901 patients with hyperlipidemia, comparing 
subcutaneous administration of Evolocumab (420 mg Q4W) vs placebo, for a period of 52 
weeks. The patients were under lipid lowering therapy, including diet alone, low intensity 
atorvastatin (10 mg), high intensity atorvastatin (80 mg) or atorvastatin 80 mg/die and 
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ezetimibe 10 mg/die. The treatment with Evolocumab resulted in significant LDL-C 
reduction in all groups [226]. RUTHERFORD-2 was a multicentre, randomised, double-
blind and placebo-controlled trial, undertaken at 39 sites in different countries around 
the world. 329 patients with heterozygous FH were randomized to receive Evolocumab 
(140 mg or 420 mg) or placebo at two weekly and monthly regimens, respectively. 
Evolocumab treatment significantly reduces LDL-C with both regimens, as compared to 
placebo after 12 weeks [227]. While RUTHERFORD-2 evaluated efficacy and safety of 
Evolocumab in heterozygous FH, TESLA trial examined 50 patients with homozygous FH 
on stable lipid lowering therapy. Addition of Evolocumab (420 mg Q4W) leads to a 
significant reduction in LDL-C by up to 31%, vs placebo [228]. OSLER-1 (Evolocumab 420 
mg Q4W) and OSLER-2 (Evolocumab 140 mg Q2W or 420 mg Q4W) confirmed, in 4465 
patients, a very strong reduction in LDL-C with Evolocumab compared to standard 
therapy [229]. Recently, the results from the FOURIER trial have been presented. The 
study enrolled 27,564 patients with cardiovascular disease and on a moderate to high 
intensity statin therapy, in 49 countries. Most patients had a history of heart attack, 
ischemic stroke and symptomatic peripheral artery disease. Patients were assigned to 
receive subcutaneous injections of Evolocumab (140 mg Q2W or 420 mg Q4W) or 
matching placebo, showing that Evolocumab is able to reduce LDL-C by 59%, compared to 
control group. Interestingly, it was observed a statistically significant 27% reduction in 
heart attack and a 21% reduction in stroke, despite no effect on cardiovascular mortality 
by itself [175]. Finally, the TAUSSIG trial (NCT01624142) is still ongoing and is evaluating 
Evolocumab therapy in 300 patients with severe FH, with the results waited for March 
2020 [219]. 
The side effects of Evolocumab are similar to those of Alirocumab.. The most common 
adverse effects are nasopharyngitis, upper respiratory tract infection, back pain and 
nausea, while the most common side effects which lead to drug discontinuation are 
myalgia, nausea and dizziness. In 2,4% individuals have been observed cardiac disorders 
including palpitations, angina pectoris and ventricular extra systoles. Anyway, the overall 
incidence of adverse effects with Evolocumab 140 mg Q2W as compared to placebo were 
43,6% vs 41%, respectively. Notably, Evolocumab and Alirocumab have been associated 
with a higher incidence of cognitive adverse events in patients [219]. 
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Bococizumab and LY3015014 
Bococizumab (RN316) is a humanized anti-PCSK9 mAb developed by Pfizer for a longer 
serum half-life and duration of action on LDL-C lowering. Phase I studies demonstrated 
that single intravenous or subcutaneous administration of Bococizumab significantly 
reduces LDL-C in patients with hypercholesterolemia, both with and without concomitant 
atorvastatin therapy [219]. Gumbiner et al. in a phase II, randomized, placebo-controlled 
study evaluated the efficacy and safety of Bococizumab in hypercholesterolemic patients 
on statin therapy but not at target LDL-C. After 12 weeks of treatment they observed a 
60% reduction in LDL-C, compared to placebo group. Of note Bococizumab is more potent 
than other LDL-C lowering mAbs, indeed several patients suspended the treatment after 4 
weeks, due to LDL-C levels lower than 25 mg/dL [205].  Bococizumab had undergone the 
large phase III SPIRE, including  SPIRE-HF trial (NCT01968980) in heterozygous FH, SPIRE-
HR (NCT01968954) and SPIRE-LDL (NCT01968967) trials which are comparing 
Bococizumab to statin therapy in patients with high atherosclerotic cardiovascular risk, 
SPIRE-1 (NCT01975376) and SPIRE-2 (NCT01975389) collecting data on safety and efficacy 
of this drug [219]. The SPIRE program was planned to involve more than 30,000 subjects 
worldwide, in order to evaluate efficacy, safety, tolerability, magnitude of reduction in 
atherogenic lipids as well as in the occurrence of major CV events. However, in November 
2016, Pfizer announced the discontinuation of the global clinical development program 
for bococizumab, due to an unanticipated attenuation of LDL-C lowering over time, as 
well as a higher level of immunogenicity and higher rate of injection-site reactions, 
compared to the other agents of this class [230]. 
LY3015014 (LY), a humanized immunoglobulin G4 (IgG4) monoclonal antibody, binds to a 
PCSK9 epitope that allows cleavage of the full-length active form of PCSK9 to the inactive 
form (52kDa), through protease cleavage at Arg218 in the catalytic domain. Preclinical 
and clinical studies demonstrated that LY binding to a site that permits normal proteolytic 
cleavage of PCSK9, resulting in a reduction of target-mediated drug disposition, increases 
potency and durability of the effect on LDL-C levels. Recently, Kastelein et al. showed that 
the administration of LY dosed Q4W (20, 120, or 300 mg) or Q8W (300 mg), in 527 
patients with primary hypercholesterolaemia, resulted in robust and durable reduction of 
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LDL-C. No clinically relevant safety issues emerged with the administration of LY, although 
the long-term effects on cardiovascular outcomes require further investigation [231]. 
4.5.6 Vaccines 
Despite mAbs based immunotherapies have significantly improved the treatment of 
several chronic diseases, they present faults that can limit patient access and clinical use. 
mAbs are relatively expensive, over the fact that they require to be injected frequently 
(once or twice a month) and at high doses (140 mg Q2W or 420 Q4W), resulting in 
tolerability issues and poor compliance. An appealing new alternative to mAbs  is the 
active vaccination against self-antigens involved in chronic diseases. The aim is to provide 
the same therapeutic effects obtained with the passive administration of mAbs, but with 
considerably reduced administrations and lower doses, and without the possibility of 
inducing drug-neutralizing immune responses [232]. In 2012, Fattori et al. demonstrated 
that immunization with human recombinant PCSK9 in mice is able to raise antibodies that 
cross-react and neutralize circulating mouse PCSK9 protein. Preventing the PCSK9/LDLR 
interaction,  they showed a considerable increased hepatic LDLR expression, paralleled 
with a reduction in plasma cholesterol levels, in the immunized mice compared to 
controls. Interestingly, these findings closely resemble those described in PCSK9 KO mice 
or in mice treated with anti-PCSK9 mAbs [233]. More recently, the AT04A anti-PCSK9 
vaccine was evaluated for its therapeutic potential in improving or even preventing 
coronary heart disease in the atherogenic APOE*3Leiden.CETP mouse model. AT04A 
vaccine, when injected in mice fed  with a western-type diet for 18 weeks in order to 
induce hypercholeterolemia and the development of atherosclerosis, reduces the total 
amount of cholesterol by 53%, atherosclerotic lesions in the aorta by 64%, and systemic 
and vascular inflammation, compared to unvaccinated mice [234]. In 2015, a phase I 
clinical study started at the Department of Clinical Pharmacology (Medical University of 
Vienna – Austria), studying AT04A and AT06A in 72 healthy people to evaluate its safety 
and activity. The study is expected to complete at the end of this year. Considering that 
the induced antibodies persist for months after a vaccination, if these findings translate 
successfully in humans, it could be developed a long-lasting therapy that just needs an 
annual booster, favouring an higher patient compliance [235].  
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4.5.7 Mimetic peptides  
Mimetic peptides are small protein-like chains designed to mimic the structure of a target 
protein in order to affect its biological activity. Mimetic peptides have high specificity, are 
relatively easy to produce and are cheaper compared to antibodies, but their routes of 
administration are limited. Recently, this approach has been used to interfere with the 
ability of PCSK9 to interact with the LDLR. In particular, have been developed mimetic 
peptides towards EGF-A (the PCSK9 binding motif on the LDLR), the catalytic domain, the 
prodomain and the C-terminal domain of PCSK9 [205]. Shan et al. demonstrated that a 
synthetic EGF-A mimetic peptide is able to inhibit PCSK9-mediated degradation of LDLR in 
HepG2 cells, as well as mouse VLDLR and, at a lower rate, ApoER2 [236]. Similarly, 
another synthetic peptide mimicking the H306Y GOF mutation in the EGF-A domain block 
the binding of secreted PCSK9 to cell surface LDLR, thus successfully increasing LDLR 
expression in HepG2 cells [237]. Pep2-8, the smallest peptide that mimics the secondary 
structure of the EGF-A domain, covering the catalytic domain of PCSK9, restores LDLR 
recycling and LDL particle uptake in PCSK9-treated HepG2 cells [238]. Beyond mimetic 
peptides to EGF-A, Saavedra and coworkers have engineered a chimeric protein using the 
Fc-region of human IgG1 fused to the PCSK9 prosegment, which interacts with 
the prosegment and the catalytic domain of the PCSK9/prosegment complex and 
allosterically modulates its function. Moreover, considering that annexin-A2 is a natural 
extrahepatic inhibitor of the PCSK9-induced LDLR degradation, small mimetic peptides to 
annexin-A2 have been proposed as a potential approach for PCSK9 inhibition. Finally, the 
PCSK9 inhibitor SX-PCK9 (Serometrix), a small peptide that interferes with the normal 
PCSK9 folding and LDLR binding, is currently  in preclinical development. Despite there are 
no clinical trials testing the use of small peptides to inhibit PCSK9 at this time, all these 
molecules directed against variable parts of PCSK9 could be an interesting approach for 
LDL-C lowering in the future [175]. 
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4.5.8 Adnectins 
Adnectins are a new family of therapeutic proteins derived from the 10th extracellular 
type III domain of human fibronectin, whose variable loops can be efficiently engineered. 
Because they are smaller compared to mAbs, adnectins can be simply modified to bind to 
their target protein (eg, PCSK9) with high specificity and affinity via transforming β-sheet 
loops, which preserve structural stability [239]. The high-affinity PCSK9-binding adnectin 
BMS-962476 (Bristol-Myers Squibb/Adnexus) was designed to target the LDLR binding site 
of PCSK9 and to prevent PCSK9-induced degradation of the LDLR. In hypercholesterolemic 
mice, which overexpress human PCSK9, a single intravenous injection of BMS-962476 is 
able to down-regulate both circulating PCSK9 and LDL-C levels. In cynomolgus monkeys 
the treatment with this adnectin reduces plasma PCSK9 levels to almost zero within 10 
min, resulting in a reduction of LDL-C by approximately 55% within 48 h, an effect that 
persists for nearly 3 weeks. Although adnectins pharmacokinetic has been shown to be 
favourable with a rapid onset of action in preclinical models, further preclinical and 
especially clinical trials are needed to assess the possible development of this agent [240]. 
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PCSK9 is a protein, mainly synthesized and secreted by the liver, which binds to specific 
target proteins and escorts them towards lysosomes for degradation [1]. The best defined 
activity of PCSK9 is its ability to modulate the hepatic uptake of LDL-C, by enhancing the 
intracellular degradation of the LDLR [187]. In humans, several mutations in PCSK9 gene 
were described, both “gain-of-function” mutations associated to FH [113] and “loss of 
function” mutations linked to low LDL-C levels [183]. These findings suggest PCSK9 
inhibitors as a promising class of drugs for the treatment of patients with severe 
hypercholesterolemia and/or at very high cardiovascular risk.  
 
Although the liver is the main regulator and target of PCSK9 [148], it is synthesized also in 
other tissues, pointing to a possible role of this protein beyond the control of hepatic 
LDLR expression [4]. In particular, the LDLR is abundantly expressed by pancreatic β cells 
in humans, mice and rats, where it plays a key role in the uptake of plasma LDL-C [2]. 
Cholesterol homeostasis is crucial for β cells function and survival, and excessive 
cholesterol accumulation causes a significant reduction in islets’ ability to secrete insulin 
in response to increased glucose levels [108].  
 
On these premises, the aim of this PhD project was to further investigate the extra-
hepatic role of PCSK9. The increasing interest in anti-PCSK9 therapies raises the question 
of whether pharmacological inhibition of PCSK9 to treat hypercholesterolaemia and 
associated cardiovascular diseases might impact on non-hepatic tissues, including 
pancreas and β cells function. Indeed, despite the increasing number of observations, the 
debate on the exact roles of PCSK9 in extrahepatic tissues is still ongoing, and as very 
effective drugs inhibiting PCSK9 have become available to the clinician, a better 
understanding of the biological roles of PCSK9 is warranted. Interestingly, in three 
different mendelian randomization studies the analysis of the effects of genetic scores 
consisting of independently inherited polymorphisms in the PCSK9 gene resulted into 
reduced LDL-C levels and cardiovascular events but was also associated with an increased 
risk of diabetes [164, 165, 241]; furthermore patients with familial hypercholesteroleamia 
(decreased LDLR function) appear to have a lower risk of diabetes [166]. These data set 
the stage for further investigating the role of PCSK9 on glucose metabolism and diabetes.
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1. Mice  
B6;129Sv-Pcsk9tm1Jdh/J male mice from the Jackson Laboratory (Bar Harbor, ME, USA) 
were backcrossed to C57Bl6J females for 10 generations. Heterozygous mutant mice from 
the F10 generation were intercrossed to generate littermates WT and PCSK9 KO mice.  
B6.129S7-Ldlrtm1Her/J male mice from the Jackson Laboratory (Bar Harbor, ME, USA) 
were backcrossed to PCSK9 KO females for 10 generations. Heterozygous mutant mice 
from the F10 generation were intercrossed to generate littermates LDLR KO and 
LDLR/PCSK9 DKO mice.  
B6.Cg-Tg(Alb-cre)21Mgn/J male mice from the Jackson Laboratory (Bar Harbor, ME, USA) 
were backcrossed to PCSK9LoxP/LoxP females (provided by Merck Research Laboratories) for 
10 generations. Heterozygous mutant mice from the F10 generation were intercrossed to 
generate littermates AlbCRE-/PCSK9 LoxP/LoxP and AlbCRE+/PCSK9 LoxP/LoxP.   
All the mice were kept under controlled light/dark cycle (12 hours of light/12 hours of 
dark) and temperature-controlled conditions (21°C). They had free access to food and 
water, except when fasting (overnight for GTT and fast and refeeding experiment, 4h for 
ITT) was required.  
 
The investigation conforms to the European Commission Directive 2010/63/EU and was 
granted approval by the “Direzione Generale della Sanità Animale e dei Farmaci 
Veterinari” of the Italian Ministry of Health (402/2015-PR, 1162/2016-PR). 
 
2. DNA isolation and genotyping  
To identify the genotype of the mice pups the Polimerase Chain Reaction (PCR) 
technology was performed, followed by agarose gel electrophoresis. DNA for PCR analysis 
was obtained from ear punches (obtained at 21 days of age), a procedure required for the 
numbering and the identification of the mice. A 2 mm punch of mouse ear was placed in 
0.5 mL of Lysis Buffer [0,5% SDS (Bio-Rad), 0.2 M NaCl (Sigma), 50 Mm Tris HCl pH 8 
(Applichem), 4 Mm EDTA (Sigma)] with 25 μL of Proteinase K (10 mg/ml – Roche) for 18 at 
56°. The addition of Phenol/Cloroform/Isoamyl alchol 25:24:1 (500 μL) and subsequently 
of Ethanol 95%(800 μL) allowed the DNA precipitation, resuspended in 50 μL deionized 
sterilized water. The PCR reaction, performed with GeneAmp – PCR system 9700 
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machinery, was prepared using the GoTaq® Flexi DNA Polymerase kit (Promega) and the 
amplification parameters were set depending on the primers.  
 
PCSK9 KO Primer 0  
PCSK9 KO Primer 1 
PCSK9 KO Primer 2 
5’-GAT TGG GAA GAC AAT AGC AGG CAT GC 
5’-ATT GTT GGA GGG AGA AGT ACA GGG GT 
5’-GGG CGA GCA TCA GCT CTT CAT AAT CT 
LDLR KO Fw Primer 
LDLR KO Rw Primer  
LDLR KO Rw Primer 2  
5’-AAT CCA TCT TGT TCA ATG GCC GAT C 
5’-CCA TAT GCA TCC CCA GTC TT 
5’-GCG ATG GAT ACA CTC ACT GC 
PCSK9 LoxP/LoxP Fw Primer 
PCSK9 LoxP/LoxP Rw Primer 
5’-GGA TAG TTC AGG GTT CAA AGC ATG GG 
5’-GGT CTC CTC CAT CAG CAC CAC AAT G 
AlbCRE Fw Primer  
AlbCRE Rw Primer 
5’-AGG TGT AGA GAA GGC ACT CAG C 
5’-CTA ATC GCC ATC TTC CAG CAG G 
 
All the primers were provided by Metabion International AG. Once the PCR is done, the 
agarose gel electrophoresis (1,5%) was performed to check the genotype of the pups, using 
GelStar™ Nucleic Acid Gel Stain (LONZA). 
 
3. Dietary regimen 
WT and PCSK9 KO mice, starting from 8 weeks of age, were fed with a Standard Fat Diet 
(SFD) or a High Fat Diet (HFD), as a model of diet-induced obesity, for 20 weeks. LDLR KO, 
LDLR/PCSK9 DKO, AlbCRE-/PCSK9LoxP/LoxP and AlbCRE+/PCSK9LoxP/LoxP mice, starting from 8 
weeks of age, were fed with a Standard Fat Diet (SFD) for 12 weeks. 
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SFD (Research Diets, Inc) 
 
Protein 19,2 g% 20 kcal% 
Carbohydrate 67,3 g% 70 kcal% 
Fat  4,3  g% 10 kcal% 
Total 3,85 kcal/g 100 kcal% 
 
Ingredients Gm  Kcal % 
Casein, 30 Mesh 200 800 
L-Cystine 3 12 
Corn Starch 452 18080.8 
Maltodextrin 10 75 300 
Sucrose 174 691.2 
Cellulose, BW200 50 0 
Soybean Oil 25 225 
Lard 20 180 
Mineral Mix S10026 10 0 
DiCalcium Phoshate 13 0 
Calcium Carbonate 5.5 0 
Potassium Citrate, H2O 16.5 0 
Vitamin Mix V10001 10 40 
Choline Bitartrate 2 0 
FD&C Red Dye #40 0.04 0 
Total 858.15 4057 
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HFD (Research Diets, Inc) 
 
Protein 24 g% 20 kcal% 
Carbohydrate 41 g%              35 kcal% 
Fat  24 g%              45 kcal% 
Total 4,13 kcal/g 100 kcal% 
     
Ingredients Gm Kcal % 
Casein, 30 Mesh 200 800 
L-Cystine 3 12 
Corn Starch 73 291 
Maltodextrin 10 100 400 
Sucrose 173 691 
Cellulose, BW200 50 0 
Soybean Oil 25 225 
Lard 178 1598 
Mineral Mix S10026 10 0 
DiCalcium Phoshate 13 0 
Calcium Carbonate 5.5 0 
Potassium Citrate, H2O 16.5 0 
Vitamin Mix V10001 10 40 
Choline Bitartrate 2 0 
FD&C Red Dye #40 0.05 0 
Total 858.15 4057 
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Both HFD and SFD were given for 12 or 20 weeks. The diet was administered 3 times a 
week and food intake was measured daily for 4 weeks during both the HFD and SFD 
treatment, to assess food consumption. Body weights were measured weekly. 
 
4. Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT) 
GTT and ITT were performed after 12 and 20 weeks of SFD or HFD treatment. For the GTT, 
mice were fasted overnight (12-16h), weighed and blood glucose was measured by 
snipping the tail and using a glucose meter (ONE-TOUCH Ultra), before and 20, 40, 60, 
120 min after intraperitoneal injection of glucose solution (2g/Kg body weight). For the 
ITT, mice were fasted for 4h, weighed and blood glucose was measured by snipping the 
tail and using a glucose meter (ONE-TOUCH Ultra). Insulin solution (0.2IU/kg body weight) 
was injected in the intraperitoneal cavity and mice were bled as described above after 20, 
40, 60, 120 min. Insulin solution was prepared from stock of 100 UI insulin solution 
(Humuline R 100 UI/mL) and was diluted in a physiological solution (NaCl 0.9%) with 3% of 
bovine serum albumin (BSA Sigma-Aldrich). At the end of both GTT and ITT the tail 
wounds were cauterized and the mice were provided with food. The area under the curve 
(AUC) was calculated for glucose clearance following GTT or ITT.  
 
5. Fasting and refeeding test 
Fasting and refeeding experiments were performed at 12 or 20 weeks. Mice were fasted 
overnight (12-16h), weighted, housed one for cage and refeed ad libitum for 4h (food was 
weighted at the beginning of the test and after the 4h, to assess food consumption for 
each animal). Blood glucose was measured by snipping the tail and using a glucose meter 
(ONE-TOUCH Ultra), both in fasting state and after 4h refeeding.  
 
6. Magnetic resonance for imaging (MRI)  
MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures 
of organs and structures inside the body. The MRI was used to monitor fat accumulation 
in the visceral (VAT) and subcutaneous (SCAT) depots after 20 weeks of HFD or SFD, in WT 
and PCSK9 KO mice. Mice were anesthetize with isoflurane during the MRI analysis. The 
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identification of fat was allowed by the different amount of water of this tissue compared 
to muscles: fat depot appeared white while muscles black. A total of 16 pictures were 
taken from the visceral area; then the area of fat depot was measured in 3 pictures per 
mouse and the average calculated. 
 
7. Plasma cholesterol and triglycerides measurement  
Blood was collected at sacrifice in Eppendorf tubes containing EDTA 0.5%. Blood samples 
were centifuged for 14 min at 7000 rpm at 4°C and plasma was collected and immediately 
stored at -20°C for assays. 
Plasma cholesterol levels were measured with ABX Pentra Cholesterol CP kit and 
according to manufacturer instructions. The calibrator curve was prepared using serial 
dilution of a cholesterol standard (200 mg/dl - ABX Pentra). The same procedure was 
followed to detect plasma triglycerides, using the appropriate triglycerides standard (200 
mg/dl - ABX Pentra) and reagents (ABX Pentra Triglycerides CP).  
 
8. Insulin, C-Peptide and PCSK9 measurement  
Blood was collected at sacrifice in Eppendorf tubes containing EDTA 0.5%. Blood samples 
were centifuged for 14 min at 7000 rpm at 4°C and plasma was collected and immediately 
stored at -20°C for assays. 
Insulin levels were measured in plasma with Mercodia Ultrasensitive Mouse Insulin ELISA 
and according to manufacturer instructions. Plasma insulin was measured also 5 min after 
intraperitoneal injection of glucose solution (2g/Kg body weight) and after a fasting and 
refeeding experiment, using blood collected from the tails. For insulin detection in 
pancreas Mercodia Mouse Insulin ELISA was used. Pancreas were processed in 350 μl of 
Tissue Protein Extraction Reagents (Thermo Fisher Scientific) containing a cocktail of 
protease and phosphatase inhibitors (Roche Diagnostics). C-peptide levels were 
measured in plasma with Mercodia Ultrasensitive Mouse C-peptide ELISA and according 
to manufacturer instructions. PCSK9 was measured on plasma aliquots collected after 
overnight fasting and stored at -80°C for up to three weeks by a commercial enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN). Plasma samples 
were diluted 50 times and then processed as per manufacturer instructions.   
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9. Western Blot Analysis   
Total cytosolic protein extracts from liver and soleus muscle were obtained by lysing 
tissues in 350 μl of Tissue Protein Extraction Reagents (Thermo Fisher Scientific) 
containing a cocktail of protease and phosphatase inhibitors (Roche Diagnostics). Twenty 
μg of proteins and a molecular mass marker (Novex® Sharp Protein Standard, 
InvitrogenTM; Life Technologies Europe BV) were separated on 4-12% sodium 
dodecylsulfate-polyacrylamide gel (SDS-PAGE; Novex® NuPAGE® 4-12% Bis-Tris Mini Gels, 
InvitrogenTM; Life Technologies) under denaturing and reducing conditions and then 
transferred to a nitrocellulose membrane by using the iBlotTM Gel Transfer Device 
(InvitrogenTM; Life Technologies). The membranes were washed with Tris-Buffered 
Saline-Tween 20 (TBS-T) and non-specific binding sites were blocked in TBS-T containing 
5% (BSA; Sigma-Aldrich) for 90 min at RT. The blots were incubated overnight at 4°C with 
anti-pAKT, (1:150; Millipore) or anti-AKT (1:1,000; Cell Signaling) (5% BSA or non-fat dried 
milk). Membranes were washed with TBS-T and then exposed for 90 min at RT to a 
diluted solution (5% non-fat dried milk) of the secondary antibodies. Immunoreactive 
bands were detected by exposing the membranes to ClarityTM Western ECL 
chemiluminescent substrates (Bio-Rad Laboratories) for 5 min and images were acquired 
with a ChemiDocTM XRS System (Bio-Rad Laboratories). Densitometric readings were 
evaluated using the ImageLabTM software. 
 
10.   Immunofuorescence staning and analysis 
For morphological studies, pancreases from wild type and transgenic mice were collected 
after sacrifice and fixed in 4% (w/v) neutral-buffered formalin, processed and embedded 
in paraffin blocks. After microwave antigen retrieval (2x5 min in 10 mM citrate buffer, pH 
6.0), 5-μm-thick sections were incubated for two hours with primary antibodies against 
hormones. The following antibodies were used: anti-insulin polyclonal from guinea pig 
(Dako; diluted 1:300), anti-glucagon polyclonal from rabbit (R&D Systems, Minneapolis, 
MN, USA; diluted 1:150), and anti-somatostatin monoclonal from rat (Millipore, diluted 
1:100), anti-LDLR (Abcam, diluted 1:300), anti PCSK9 (Cayman,  diluted 1:50). Staining 
with primary antibody was followed by incubation for one hour with rhodamine-
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conjugated anti-guinea pig IgG, FITC-conjugated anti-mouse, Cy5-conjugated anti-rabbit 
and Cy5 or FITC-conjugated anti-rat IgG (Jackson ImmunoResearch Laboratories).  
 
11.  Image acquisition and analysis 
Microscopic analysis was performed using a Zeiss (Oberkochen, Germany) Axiovert 200 
inverted fluorescence microscope equipped with a Retiga SRV charge-coupled device 
camera (QImaging, Surrey, BC, Canada). Briefly, single-stain wildfield 
immunofluorescence images were acquired using identical parameters (acquisition time 
and gain), deblurred using the Nearest Neighbor algorithm (Image ProPlus 6.2 3D 
Analyser; Media Cybernetics, Rockville, MD) and merged. To quantify the islet’s area and 
composition on digital images, the islet profile was manually outlined and a macro was 
created in order to automatically quantify the green (somatostatin)-, red (insulin)- and 
blue(glucagon)-stained areas within the islet regions. For islet composition, single 
hormone staining was expressed as a percentage of total islet area 
(insulin+glucagon+somatostatin-stained areas). For each subgroup, a minimum of five 
islets per pancreas were imaged, in six different animals. Experiments were performed in 
duplicate.  
 
12.  Pancreatic islets isolation and FACS analysis 
Islets were isolated from wild type and transgenic mice by injection of 4 ml type II 
collagenase solution (1 mg/mL, Sigma-Aldrich) within the pancreas. After surgical excision 
of the pancreas, it was incubated at 37 °C for 10 min and then washed 3 times in 
minimum essential medium (MEM, Sigma) to remove collagenase. Undigested tissue was 
removed using a 70 µm filter. Pancreatic islets were separated by Percoll PLUS gradient 
(GE Healthcare Europe, Milan, Italy), collected and processed for flow cytometry analysis. 
Antibodies for FACS were used at 1:200 dilutions unless otherwise specified, optimal 
antibody concentrations for staining were calculated based on manufacturer instructions. 
Cells from pancreatic islets were suspended in 100 µL of PBS/BSA 5% and incubated with 
0.5 µL of Fc block (BD Pharmingen, purified Rat anti-Mouse CD16/CD32, Cat#553142) and 
with primary antibody against LDLR (Cayman LDL Receptor Polyclonal Antibody, 
Cat#10007665) for 30 minutes at 4°C. Samples were washed twice with PBS/BSA 5% and 
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re-suspended in 100 µL of PBS/BSA 5% with goat anti-rabbit IgG secondary antibody Alexa 
Fluor 633 (Thermofisher Scientific, Cat#A-21070) and incubated for 30 minutes at 4°C. 
After two wash with PBS/BSA 5%, samples were diluted in 500 µL of PBS/BSA 5% and 
acquired with Novocyte (ACEA biosciences) and analyzed using Novoexpress 3000 (ACEA 
biosciences). 
 
13.  Cholesterol and fatty acid content in pancreatic islets 
Pancratic islets’ homogenates, after thawing and addition of stigmasterol, nonadecanoic 
acid and cholesteryl heptadecanoate as internal standards,  were extracted three times 
with CHCl3/CH3OH 2:1 plus KCl 0,05%. The lipid layers were collected, concentrated and 
loaded onto a TLC (hexane:diethylether:acetic acid 80:20:1). After run and spraying with 
dichlorofluorescein, the spots corresponding to FC, FFA and CE were removed and 
processed as follows. Those containing FC were extracted twice with hexane/isopropanol 
3:2, concentrated and detected by gas-liquid chromatography (DANI 1000 equipped with 
a HTA autosampler; column MEGA FFAP EXT) without derivatization at a constant 
temperature of 260°C for 10 minutes. The spots containing CE and FFA were derivatized 
by methanolic HCl 3N for 20-120 minutes at 80°C, extracted by hexane/water and their 
fatty acid content analyzed by GLC (same equipment as before, with temperature raising 
from 120 to 260 °C, total run 40 minutes).  
The mass of FC was calculated by comparing its AUC with that of the internal standard 
(stigmasterol), while those of FFA and CE was obtained after summing the AUC of their 
fatty acids and comparison with that of nonadecanoic acid (FFA) or cholesteryl 
heptadecanoate (CE). In the case of CE and FFA, obviously also a qualitative profile is 
available. Each lipid mass was then normalized by sample protein content, evaluated by 
the bicinchoninic acid, and expressed as ug lipid/mg protein.   
 
14.  RNA isolation and real time quantitative polymerase chain reaction 
(RT-PCR) 
RNA was isolated from pancreatic islets (20 mg) collected as described above, using 
NucleoSpin RNA kit (MACHEREY-NAGEL).  0,5 – 1 ng of RNA was reverse transcripted with 
iScript™ Reverse Transcription Supermix for RT-qPCR (BioRad), according to manufacturer 
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instructions. 2 μL of cDNA were amplified by realtime quantitative PCR with 1X Syber 
green universal PCR mastermix (BioRad, Italy). The specificity of the Syber green 
fluorescence was tested as described [242]. Each sample was analyzed in duplicate using 
the CFX-Cycler (BioRad). The PCR amplification was related to a standard curve ranging 
from 10-11 mol/L to 10-14 mol/L and data were normalized for the housekeeping gene 
ribosomal protein L13a (RLP13a) [243]. 
 
ABCA1 Fw Primer 
ABCA1 Rw Primer 
5’-GGTTTGGAGATGGTTATACAATAGTTGT 
5’-TTCCCGGAAACGCAAGTC 
ABCG1 Fw Primer 
ABCG1 Rw Primer  
5’-TTCATCGTCCTGGGCATCTT 
5’-CGGATTTTGTATCTGAGGACGAA 
LXR Fw Primer 
LXR Rw Primer 
5’-CGACAGAGCTTCGTCCACAA 
5’-GCTCGTTCCCCAGCATTTT 
SREBP2 Fw Primer  
SREBP2 Rw Primer 
5’-TGACTAAGTCCTTCAACTCTATGATTTTG 
5’-GCGGCAAACACACAATATCATTG 
HMGCoA Fw Primer  
HMGCoA Rw Primer 
5’-TGTGGTTTGTGAAGCCGACAT 
5’-TACACCATAGCTTCCGTAGTTGTC 
ACAT1 Fw Primer  
ACAT1 Rw Primer 
5’-TGGCACGAATTGCAGCAT 
5’-GCAGGCGCAAGTGGAAAA 
LDLR Fw Primer  
LDRL Rw Primer 
5’-GTGTGACCGTGAACATGACTG 
5’-CACTCCCCACTGTGACACTTGA 
 
 
15.  Statistical analysis 
For animal studies, statistical analyses were performed with GraphPad Prism6 or with 
IBM-SPSS statistic 19. Data were analyzed by the Wilcoxon rank-sum test or by ANOVA 
with repeated measures for main effects of treatment time and genotype, followed by a 
Bonferroni post hoc analysis. Data are presented as mean ± SEM. A P value <0.05 was 
considered statistically significant.  
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1. Setting of a mouse model of obesity and metabolic dysfunction 
 
Weight gain, lipid profile and fat distribution 
 
In order to setting an animal model of metabolic dysfunction, C57BL/6 WT mice were fed 
a SFD or HFD for 20 weeks. We assessed whether a lipid-rich diet causes alterations in 
metabolic parameters evaluating plasma lipid profile, body weight, fat distribution and 
glucose homeostasis.  
Starting from the 10th week of diet, mice fed a HFD gained more weight compared to 
littermates fed a SFD, difference that became significant during the last weeks (13.1±1.9 g 
vs 7.55±0.6 g, 20 weeks, p<0.05) (Fig 1A). At the end of the 20 weeks of diet, also the total 
body weight of mice fed a HFD resulted strongly increased compared to controls 
(37.2±2.4 g vs 29.7±2.6 g, p<0.05). Despite this, food intake was measured daily and no 
difference occurred between the two experimental groups (Fig. 1B). 
As expected, mice fed a HFD showed a significant increase in both circulating cholesterol 
and triglycerides levels, compared to mice fed a SFD (123.4±5.3 mg/dl vs 79.8±11.0 mg/dl 
and 61.6±3.7 mg/dl vs 38.6±4.2 mg/dl, respectively, p<0.05) (Fig. 1C/1D). 
Regarding the fat distribution, we evaluated both the visceral adipose tissue (VAT) and 
the subcutaneous adipose tissue (SCAT) accumulation. Mice fed a HFD presented a 
significantly increased VAT accumulation when compared to mice fed a SFD (+55%, 
p<0.05), as well as an enhanced SCAT content (+65% vs SFD, p<0.05) (Fig. 1E). 
Interestingly, also the MRI axial views showed a different fat distribution in the abdomen 
of SFD WT mice and HFD WT mice (Fig. 1F).  
 
Glucose metabolism 
 
To evaluate the effect of a lipid-rich diet on glucose metabolism, we performed GTT after 
12 weeks of SFD or HFD. In spite of similar plasma glucose levels at baseline (o/n fasting), 
following i.p. glucose injection (2g/Kg body weight), C57BL/6 WT mice fed a HFD showed 
a significant increased glycemia, compared to those fed a SFD (Fig. 2A). The increase of 
the plasma glucose AUC confirmed the delay in glucose clearance in HFD WT mice, 
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compared to control group (AUC +50% vs SFD; p<0,05) (Fig. 2B). GTT was performed also 
after 20 weeks of diet, obtained similar results (Fig. 2C/2D).  
Once shown that a lipid-rich diet is associated with an impaired glucose tolerance in our 
experimental groups, we investigated whether this effect was the consequence of an 
impaired insulin tolerance. ITT (4h fasting) was performed in C57BL/6 WT mice, after 12 
weeks and 20 weeks of SFD or HFD. The decrease in plasma glucose levels, after i.p. 
insulin injection (0.2IU/kg body weight), was significantly lower in mice fed a HFD, 
compared to mice fed a SFD,  suggesting the presence of insulin resistance under a lipid-
rich diet state (Fig. 2E/2F). 
 
The observation that mice fed a HFD developed alterations in weight gain and lipid 
metabolism, paralleled with impaired glucose tolerance and insulin resistance, confirmed 
that we  successfully set a mouse model of obesity and metabolic dysfunction.  
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Figure 1. Weight gain and daily food intake of C57BL/6 WT mice fed a standard fat diet (SFD) or 
high fat diet (HFD) are shown in panel A and B. Panel C and D show the levels of circulating 
cholesterol and triglycerides of mice fed with SFD or HFD. Weight of visceral adipose tissue (VAT) 
and subcutaneous adipose tissue (SCAT) is presented in panel E. Weight of each adipose tissue 
was normalized by total body weight. Data are shown as means ± SEM; n=8 mice per group; 
*p<0.05. Panel F reports representative magnetic resonance imaging axial views of C57BL/6 WT 
fed with SFD or HFD. 
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Figure 2. IPGTT was performed and plasma glucose levels were measured at 0, 20, 40, 60, and 120 
mins.  Data in mice fed a SFD or HFD for 12 weeks or 20 weeks and the AUC for glucose are 
presented in panels A to D. IPITT was performed and plasma glucose levels were measured at 0, 
20, 40, 60, and 120 mins.  Data in mice fed a SFD or HFD for 12 weeks or 20 weeks are presented 
in panels E and F.  Data are shown as means ± SEM; n = 8 mice per group. *p<0.05. 
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2. Impact of PCSK9 deficiency on lipid metabolism and ectopic fat 
accumulation 
 
Once characterized our mouse model, we focused on the metabolic role of PCSK9, both in 
a physiological condition (SFD) and in a state of obesity and metabolic syndrome (HFD). 
Weekly weigh gain and daily food intake of WT and PCSK9 KO mice, fed a SFD or HFD for 
20 weeks, were recorded. Interestingly, the absence of PCSK9 did not impact neither the 
weight gain or the food intake, with both diets (Fig. 3A to 3D). 
Plasma cholesterol and triglycerides levels were measured in all experimental groups. 
Firstly, we confirmed the difference between mice fed a SFD and mice fed a HFD shown in 
the characterization of the model (p<0.05). Moreover, as expected, PCSK9 KO mice 
exhibited significantly lower plasma cholesterol levels compared to WT mice (51.8±6.3 vs 
81.2±9.1 mg/dl and 86.1±4.7 mg/dl vs 118.6±7.2 mg/dl, SFD and HDF respectively, 
p<0.05), while no difference in plasma triglycerides concentrations arose both with SFD 
and HFD (Fig. 3E and 3F).  
WT and PCSK9 KO mice presented a different fat distribution in the abdomen, with both 
diets. Specifically, PCSK9 deficiency was associated with a significantly increased VAT 
accumulation when compared to WT littermates (+20% with SFD, +50% with HFD), while 
no differences were observed in SCAT (Fig. 4A/4B). Representative MRI images of the fat 
distribution in the abdomen of WT and PCSK9 KO mice are reported in Fig 4C.   
 
Here we showed that PCSK9 deficiency, which results in reduced circulating cholesterol 
levels, is associated with an increased ectopic fat accumulation, both in a physiological 
condition and in a state of metabolic dysfunction. This observation raises the question of 
a possible role of PCSK9 in modulating lipids delivery and accumulation in peripheral 
tissues. 
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Figure 3. Weight gain and daily food intake of WT and PCSK9 KO mice fed a standard fat diet (SFD) 
or high fat diet (HFD) are shown in panels A to D. Panel E and F represent the levels of circulating 
cholesterol and triglycerides of WT and PCSK9 KO mice, fed a SFD or HFD for 20 weeks. Data are 
shown as means ± SEM; n=8 mice per group; *p<0.05.  
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Figure 4.  Weights of visceral adipose tissue (VAT) and subcutaneous adipose tissue (SCAT) of WT 
and PCSK9 KO mice, fed a SFD or HFD for 20 weeks, are shown in panel A and panel B. Weight of 
each adipose tissue was normalized by total body weight. Data are shown as means ± SEM; n=8 
mice per group; *p<0.05. Representative magnetic resonance imaging axial views of WT and 
PCSK9 KO mice are presented in panel C. 
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3. PCSK9 deficiency results in impaired glucose tolerance but not in insulin 
resistance 
 
Subsequently, we turned our attention to the role of PCSK9 in glucose metabolism. To 
evaluate the impact of PCSK9 deficiency on glucose homeostasis, we initially performed 
GTT in WT and PCSK9 KO mice, fed a SFD or a HFD. In spite of similar plasma glucose 
levels at baseline, following i.p. glucose injection (2g/Kg body weight), the absence of 
PCSK9 resulted in a significant delay of glucose clearance, in both the SFD (Fig.5A to 5D) 
or the HFD (Fig.6A to 6D) groups, after 12 or 20 weeks of diet. Also the plasma glucose 
AUC was significantly higher in PCSK9 KO mice compared to WT littermates, in all 
conditions (Fig. 5C/D, 6C/D). The observation that PCSK9 KO mice presented glucose 
intolerance following GTT, despite comparable baseline glucose levels (following 
overnight fasting), prompted us to perform a fast and refeeding experiment to better 
understand possible differences in plasma glucose levels under physiological conditions. 
After an overnight fasting and ad libitum refeeding (4h), PCSK9 KO mice were 
characterized by a significant increase in plasma glucose levels compared to WT 
littermates (266 ± 14  mg/dl vs 216± 3  mg/dl with SFD; 322 ± 13  mg/dl vs 252 ± 9  mg/dl 
with HFD, p<0.05), in spite of similar food consumption (2,27 ± 0,43 g/4h vs 2,18 ±0,38 
g/4h with SFD; 2,13 ± 0,26 g/4h vs 2,25 ±0,28 g/4h with HFD) (Fig. 5E/F, 6E/F).  
 
These results pointed out the presence of impaired glucose tolerance in PCSK9 KO mice 
and set the stage for investigating whether this effect was the consequence of impaired 
insulin tolerance. 
 
To answer this question, ITT was performed in WT and PCSK9 KO mice, after a 4h fast. 
The decrease in plasma glucose levels, after i.p. insulin injection (0.2IU/kg body weight), 
was similar in WT and PCSK9 KO mice, fed both a SFD (Fig.7A and 7B) or a HFD (Fig.7C and 
7D), after 12 or 20 weeks of diet. These results exclude the presence of insulin resistance 
under PCSK9 deficient state. Moreover, we measured the ratio between phosphorylated 
Akt vs total Akt, as an index of downstream activation of the insulin receptor [244], in the 
liver (Fig. 7E) and in the soleus muscle (Fig 7F) of mice fed a SFD. Interestingly, in these 
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tissues pAkt/Akt ratio was similar in WT and PCSK9 KO mice, suggesting that downstream 
activation of insulin receptor might not be affected by PCSK9 deficiency.  
 
GTT, ITT and fasting and refeeding experiments revealed a possible key role of PCSK9 in 
the regulation of glucose metabolism. PCSK9 KO mice presented impaired glucose 
tolerance, independent of the type of diet used (high fat or standard fat), but no insulin 
resistance. IPGTT allowed us to bypass the contribution of GLP-1 on glucose homeostasis, 
which could interfere during the fasting and refeeding experiment. Several open 
questions led us to further investigate the mechanisms at the basis of these observations.  
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Figure 5.  IPGTT was performed and plasma glucose levels were measured at 0, 20, 40, 60, and 
120 mins.  Data in WT and PCSK9 KO mice, fed a SFD for 12 weeks or 20 weeks and the 
corresponding AUC for glucose, are presented in panels A to D. Panel E and F show plasma 
glucose levels  and food intake of WT and PCSK9 KO mice after a fasting (overnight) and refeeding 
(4h) experiment. Data are shown as means ± SEM; n = 8 mice per group. *p<0.05. 
 
 Results 
88 
 
 
 
Figure 6.  IPGTT was performed and plasma glucose levels were measured at 0, 20, 40, 60, and 
120 mins.  Data in WT and PCSK9 KO mice, fed a HFD for 12 weeks or 20 weeks and the 
corresponding AUC for glucose, are presented in panels A to D. Panel E and F show plasma 
glucose levels and food intake of WT and PCSK9 KO mice after a fasting (overnight) and refeeding 
(4h) experiment. Data are shown as means ± SEM; n = 8 mice per group. *p<0.05. 
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Figure 7.  IPITT was performed and plasma glucose levels were measured at 0, 20, 40, 60, and 120 
mins.  Data in mice fed a SFD for 12 weeks or 20 weeks are reported in panels A and B.  Data in 
mice fed a HFD for 12 weeks or 20 weeks are presented in panels C and D. Data are shown as 
means ± SEM; n = 8 mice per group. The pAkt/Akt ratio, is presented for the liver (E) and the 
soleus muscle (F) for PCSK9 KO and WT mice, fed a SFD. Data are shown as means ± SEM; n = 5 
mice per group. 
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4. PCSK9 deficiency results in the impairment of insulin secretion and 
histological abnormalities in pancreatic islets 
 
To clarify the mechanisms causing impaired glucose tolerance in our mouse model, we 
subsequently investigated the role of PCSK9 on insulin production and pancreatic β-cells 
function. Interestingly, plasma insulin and C-peptide levels were significantly decreased in 
PCSK9 KO mice compared to WT littermates (Fig. 8A/8B), suggesting that PCSK9 
deficiency might impair insulin secretion. As a further confirmation, following i.p. glucose 
injection, plasma insulin levels increased to lower extent in PCSK9 KO mice compared to 
WT animals (Fig. 8C). Similarly, following fast and refeeding experiment, a reduced 
increase in plasma insulin levels was observed in the absence of PCSK9 (Fig. 8D).  
On the contrary, pancreatic insulin content was significantly increased in PCSK9 KO mice 
compared to WT controls (Fig 9A). The evaluation of pancreatic islets morphology 
revealed that PCSK9 KO mice islets present an irregular shape (Fig 9B), a larger size 
(10022±2802 um2 vs 5061±1843 um2, p<0.05) (Fig.9C), and a significant increase in 
insulin positive areas (8843±1432 um2 vs 3215±508 um2, p<0.05) (Fig. 9D) compared to 
WT littermates. 
We confirmed these data also in PCSK9 KO and WT mice, fed a HFD, evaluating plasma 
insulin levels, pancreatic insulin content and pancreatic islets morphology (Fig. 10). 
Representative images of pancreatic islets of WT and PCSK9 KO, fed a SFD or a HFD, for 20 
weeks, are presented in Fig. 10 C/D.  
 
Here we observed that PCSK9 deficiency is associated with decreased plasma insulin and 
C-peptide levels, a finding paralleled by altered pancreatic morphology and insulin 
content. These data suggested an impaired beta cells function in PCSK9 KO mice, 
independent of the type of diet used, and promped us to further investigate the 
mechanisms responsible. 
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Figure 8.  Plasma insulin and C-peptide levels of WT and PCSK9 KO mice, fed a SFD, are shown in 
panels A and B. Plasma insulin levels before and after 5’ of IPGTT are presented in panel C 
(*p<0.05 vs 0; $p<0.05 vs 5’ WT) while following fasting (overnight) and refeeding (4h) experiment 
are presented in panel D (*p<0.05 vs WT; $p<0.05 vs Fasted KO). Data are shown as means ± SEM; 
n = 8 mice per group.  
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Figure 9.  Pancreatic insulin content in PCSK9 KO and WT mice, fed a SFD, is shown in panels A. 
Data are shown as means ± SEM; n = 8 mice per group. Pancreatic islets morphology shows larger 
islets in PCSK9 KO mice compared to WT with significantly increased insulin positive areas (panels 
B to D).  A representative image is presented in panel B; data in panels C and D are shown as 
mean ± SEM of 6 to 8 representative sections for each pancreas (8 animals for each group); 
*p<0.05. Scale bar in panel C: 30 μm.  
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Figure 10. Plasma insulin levels and pancreatic insulin content were measured in PCSK9 KO and 
WT mice fed a HFD (panel A and panel B). Data are shown as means ± SEM; n = 8 mice per group. 
*p<0.05. Representative images of pancreatic islets of WT and PCSK9 KO, fed a SFD (panel C) or a 
HFD (panel D) for 20 weeks, show differences in islets morphology between the two groups. n = 8 
mice per group. 
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5. PCSK9 effect on glucose metabolism is dependent on the presence of 
the LDLR 
 
In order to further investigated the molecular mechanisms responsible for the phenotype 
observed in PCSK9 KO mice, we focused our attention on the LDLR. The LDLR is 
abundantly expressed on the surface of pancreatic β cells, where it plays a key role in the 
uptake of LDL [2]. Moreover, increased β cells cholesterol content was frequently 
associated with decreased insulin secretion [245, 246].   
Firstly, to evaluate the impact of PCSK9 on the pancreatic expression of the LDLR, we 
performed immunofluorescence analysis of pancreatic sections from WT and PCSK9 KO 
mice. In agreement with previous observation [156], we showed that LDLR (blue signal) 
colocalizes with insulin positive areas (red signal), confirming its considerable expression 
on the surface of pancreatic β cells (Fig. 11). Interestingly, flow cytometry analysis 
showed that the LDLR expression was significantly increased in the pancreatic islets 
isolated from PCSK9 KO animals compared to WT littermates (Fig. 12). In addition to 
increased LDLR expression, pancreatic islets from PCSK9 KO mice presented higher 
cholesterol esters content compared to WT islets, together with significant changes in 
fatty acid lipidome (Fig. 13A). This impaired lipid profile was paralleled by the 
downregulation of genes involved in cholesterol biosynthesis and uptake, including 
HMGCoA-R and LDLR and the increase of the expression of ACAT1, which promotes 
cholesterol esterification. A modest but not significant increase was also observed in 
genes involved in cholesterol efflux, such as ABCA1, ABCG1 and LXR (Fig. 13B). 
To further test the hypothesis that the observed phenotype in PCSK9 KO mice could 
dependent on the impact on LDLR levels, we create a double KO animal model, 
PCSK9/LDLR DKO. GTT and ITT were performed in PCSK9/LDLR DKO mice and LDLR KO 
littermates, fed a SFD. The delayed glucose response observed in PCSK9 deficient 
conditions was not observed in PCSK9/LDLR DKO mice and, indeed, GTT and ITT curves 
were superimposable between the two animal groups (Fig. 14A and 14E) and similar to 
those observed in WT animals. Also the plasma glucose AUC during GTT was similar in the 
two experimental groups (Fig. 14B). Fast and refeeding experiments confirmed these 
data, showing no difference in plasma glucose levels between PCSK9/LDLR DKO and LDLR 
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KO mice (190±6 mg/dl for PCSK9/LDLR DKO compared to 191±7 mg/dl for LDLR KO mice), 
paralleled with similar food consumption during the 4h of fasting (Fig. 14C and 14D). 
Finally, we demonstrated that PCSK9/LDLR DKO mice and LDLR KO littermates were 
characterized by similar levels of both plasma and pancreatic insulin (5.17±1.08 ng/ml vs 
4.67±1.25 ng/ml, p=ns) (72.0±21.7 ng/mg of tissue vs 77.7±23.1 ng/mg of tissue p=ns) 
(Fig. 15A and 15B). The evaluation of pancreatic islets morphology revealed no difference 
in islets shape, size and insulin positive areas between PCSK9/LDLR DKO and LDLR KO 
mice, whose features are similar to those observed in WT animals (Fig. 15 C to E).  
 
Here we demonstrated that PCSK9 is able to modulate the expression of the LDLR also at 
the pancreatic level. Moreover, the observations that glucose tolerance, insulin tolerance, 
plasma insulin levels and pancreatic islets morphology in DKO were similar to those of 
control mice, suggest the key role of the LDLR in driving PCSK9 dependent pancreatic 
dysfunction.  
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Figure 11. Representative pictures of pancreatic islets from WT and PCSK9 KO mice. The islets 
were stained for insulin, somatostatin and LDLR, and the results indicated that LDLR colocalizes 
with insulin positive areas (beta cells).  Scale bar: 30 μm.  
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Figure 12. Representative panel for LDLR expression in pancreatic islets isolated from WT mice 
(upper lane) and PCSK9 KO mice (lower lane). Unstained cells, cells stained only with Alexa Fluor 
655 and cells stained with anti-LDLR are shown. The panel presents the overlay of LDLR 
fluorescence intensity in PCSK9 KO and WT mice and the difference (data are shown as mean ± 
SEM, n=5, p<0.05).  
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Figure 13. Cholesterol esters and fatty acids content were measured in pancreatic islets from 
PCSK9 KO and WT mice (panel A). The expression of genes related to cholesterol biosynthesis, 
uptake and efflux, and the expression of ACAT1 was evaluated in pancreatic islets isolated from 
PCSK9 KO and WT mice (panel B). Data presented in panel A (*p<0.05; Unpaired T Test; n = 3 mice 
per group) and B (*p<0.05; T Test; n = 6 mice per group) are shown as means ± SEM. 
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Figure 14.  IPGTT was performed and plasma glucose levels were measured at 0, 20, 40, 60, and 
120 mins. Data in LDLR KO and PCSK9/LDLR DKO mice, fed a SFD for 12 weeks, and the 
corresponding AUC for glucose, are presented in panels A and B. Panel C and D show plasma 
glucose levels and food intake of LDLR KO and PCSK9/LDLR DKO mice after a fasting (overnight) 
and refeeding (4h) experiment. IPITT was performed in mice fed a SFD for 12 weeks and plasma 
glucose levels measured at 0, 20, 40, 60, and 120 mins are reported in panels E.  Data are shown 
as means ± SEM; n = 8 mice per group. 
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Figure 15.  Plasma insulin levels and pancreatic insulin content of LDLR KO and PCSK9/LDLR DKO 
mice are presented in panel A and panel B. Panel C shows a representative image of pancreatic 
islet morphology of PCSK9/LDLR DKO, LDLR KO and WT mice, while panels D and E present data 
on pancreatic islets size and insulin positive areas size. Data in panels A and B are shown as mean 
± SEM; n = 8 mice per group. Data in panels D and F are shown as mean ± SEM of 6 to 8 
representative sections for each pancreas (8 animals for each group). 
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6. Circulating PCSK9 does not impact glucose metabolism and beta cells 
function 
 
Despite PCSK9 is mainly produced and released by the liver, it is also synthesized to a 
relevant amount in other tissues, such as the brain, the intestine and the pancreas [1]. 
Here we investigated if the phenotype observed in PSCK9 KO (full body) mice depends on 
circulating liver-derived PCSK9 or on PCSK9 produced at the pancreatic level. 
Firstly, we demonstrated that in pancreatic islets of WT mice PCSK9 colocalizes with 
somatostatin positive cells (delta cells) but not with alpha or beta cells (Fig. 16A). As 
expected, the analysis of islets derived from PCSK9 KO mice confirmed the absence of the 
protein in delta cells of these animals (Fig. 16B). 
To dissect out the role of circulating liver-derived PCSK9 from those produced in the 
pancreas, we tested glucose metabolism in SFD fed liver-specific PCSK9 KO mice. PCSK9 
mRNA expression was almost abolished in the liver of AlbCre+/PCSK9LoxP/LoxP mice (Fig. 
17A). As a consequence, PCSK9 protein was almost undetectable in plasma from 
AlbCre+/PCSK9LoxP/LoxP, while in AlbCre-/PCSK9LoxP/LoxP mice plasma PCSK9 levels were 
around 10 fold higher (Fig. 17B). As expected, plasma cholesterol levels in 
AlbCre+/PCSK9LoxP/LoxP mice were significantly lower compared to AlbCre-/PCSK9LoxP/LoxP 
(41.8±7.2 mg/dl vs 68.5± 10.2 mg/dl p<0.05) and similar to those observed in PCSK9 KO 
mice (51.1±14.0 mg/dl), further confirming the key role of circulating, liver-derived PCSK9 
on plasma cholesterol levels (Fig. 17C). On the contrary, PCSK9 mRNA expression in 
pancreas was similar between AlbCre+/PCSK9LoxP/LoxP and  AlbCre-/PCSK9LoxP/LoxP mice (Fig. 
17A), also confirmed through immunofluorescence analysis of pancreatic islets (Fig. 17D). 
Flow cytometry analysis revealed that LDLR expression (Fig. 18A) was similar in pancreatic 
islets from AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice and the same was true for 
cholesterol esters levels (Fig. 18B).  
Once characterized our model, we focused our attention on glucose metabolism. Of note, 
AlbCre+/PCSK9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice presented similar GTT and ITT 
curves (Fig. 19A/B), and the same was true for plasma glucose levels following fast and 
refeeding experiments (194±8 mg/dl for AlbCre+/Pcsk9LoxP/LoxP mice compared to 192± 5 
mg/dl for AlbCre-/Pcsk9LoxP/LoxP mice; p=ns) (Fig. 19C/D). Pancreatic insulin content was 
 Results 
102 
 
similar in the two animal models (133.6±21.1 ng/mg of tissue vs 119.1±19.3 ng/mg of 
tissue for AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice; p=ns) (Fig. 19E), as well as 
the insulin positive areas (Fig. 19F).  
 
Thus, here we reported that liver-selective PCSK9 KO mice have PCSK9 plasma levels 
below the detection limit, while maintaining PCSK9 production in other tissues including 
the pancreas. These mice presented plasma and pancreatic insulin levels, LDLR expression 
as well as pancreatic islets cholesterol esters levels similar to those of control mice, 
suggesting that the impaired glucose metabolism observed in PCSK9 KO (full body) mice 
depends on PCSK9 produced locally in the pancreas.   
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Figure 16. Panel A shows a representative image of the immunofluorescence of pancreatic islets 
from WT mice indicating that PCSK9 colocalizes with somatostatin positive areas (delta cells). 
Panel B presents representative images of PCSK9 expression in pancreatic islets from WT and 
PCSK9 KO mice. Scale bar: 30 μm. 
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Figure 17. Panel A shows PCSK9 mRNA expression in the liver or in the pancreas of 
AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice. Panel B presents plasma PCSK9 levels of 
AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice, while panel C shows  the levels of circulating 
cholesterol in the same animal groups. Representative images of PCSK9 expression, which 
colocalizes with somatostatin positive areas (delta cells), of pancreatic islets from 
AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice; Scale bar: 30 μm (Panel D). Data in panels A, 
B and C are shown as means ± SEM; n=8 mice per group; *p<0.05.  
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Figure 18. Panel A shows a representative panel for LDLR expression in pancreatic islets isolated 
from AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice. The panel presents the overlay of LDLR 
fluorescence intensity in AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice and the 
quantification (data are shown as mean ± SEM n=5). Panel B shows cholesterol esters and fatty 
acids content of pancreatic islets from AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice. Data 
are shown as means ± SEM; n = 8 mice per group. 
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Figure 19. Plasma glucose levels following IPGTT (0, 20, 40, 60, and 120 mins) of 
AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice, fed a SFD for 12 weeks, are presented in 
panels A. Panel B shows plasma glucose levels in AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP 
mice following IPITT (0, 20, 40, 60, and 120 mins). Panel C and D show plasma glucose levels and 
food intake of the same mice after a fasting (overnight) and refeeding (4h) experiment. Pancreatic 
insulin content and insulin positive areas of AlbCre+/Pcsk9LoxP/LoxP and AlbCre-/Pcsk9LoxP/LoxP mice 
are presented in panel E and panel F. Data are shown as means ± SEM; n = 8 mice per group. 
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PCSK9 is a protein, initially discovered to be involved in neuronal development and 
differentiation, which binds to specific proteins and escorts them towards 
endosomes/lysosomes compartments for degradation [1, 3]. PCSK9 came to attention of 
the scientific community in 2003, when it was found mutated in patients affected by FH 
[113], pointing out its key role in lipid metabolism. The LDLR has been identified as the 
main target of PCSK9 [247]. Indeed, mice lacking PCSK9 exhibit an increased hepatic LDLR 
expression, resulting in an increased clearance of circulating LDL-C and 
hypocholesterolemia [248], while PCSK9 overexpression induces a 2-fold increase in 
plasma cholesterol levels [124]. In humans, several mutations in PCSK9 gene were 
described over the years, both “gain-of-function” mutations associated to 
hypercholesterolemia [113] and “loss of function” mutations linked to low levels of LDL-C 
[183, 188].  
On these premises, anti-PCSK9 therapies have been developed and monoclonal 
antibodies against PCSK9 are currently available for the treatment of patients with severe 
hypercholesterolemia and/or at very high cardiovascular risk.  
Although the liver is the main contributor to circulating PCSK9 and its most important 
target [148], other tissues produce PCSK9, pointing to a possible role of this protein 
beyond the control of the hepatic LDLR expression [4]. Of note, the LDLR is abundantly 
expressed by pancreatic β-cells in humans, mice and rats, where it plays a key role in the 
uptake of plasma LDL [2, 157]. The accumulation of cholesterol in pancreatic islets has 
been associated with reduced glucose induced insulin secretion [108] and cellular toxicity 
[245, 249], pointing to the critical role of cholesterol metabolism in this tissue. As a 
consequence of the LDLR-mediated cholesterol influx in β-cells, genetic and acquired 
conditions increasing LDLR expression, should be associated with altered glucose 
metabolism. Loss of function variants in the HMGCoA reductase which, by limiting cellular 
cholesterol biosynthesis, favor cholesterol uptake via LDLR, are associated with increased 
risk of developing diabetes [164]. On the contrary, FH subjects bearing a loss of function 
mutation in the LDLR, present a decreased risk of diabetes [166]. Also pharmacological 
treatments resulting in increased LDLR expression, such as statins, increase the risk of 
diabetes [250], thus indicating that excessive LDLR activity could be the driver of β-cells 
dysfunction and diabetes. Interestingly, the same is true for loss of function variants in 
PCSK9. Indeed, in three different mendelian randomization studies the analysis of the 
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effects of genetic scores consisting of independently inherited polymorphisms in the 
PCSK9 gene resulted into reduced LDL-C levels and cardiovascular events but was also 
associated with an increased risk of diabetes [164, 165, 241]. On these premises and 
given the great interest in anti-PCSK9 therapies, we investigated in detail how PCSK9 
deficiency could impact on non-hepatic tissues, especially pancreas and β-cells function. 
 
The influence of PCSK9 on lipid metabolism and glucose homeostasis was evaluated in 
two different conditions: a state of obesity and metabolic dysfunction (HFD) and a 
physiological condition (SFD). The use of a lipid-rich diet, compared to a standard diet, 
allowed us to investigate the role of PCSK9 in different metabolic settings, thus increasing 
the knowledge about its biological functions. Firstly we demonstrated that C57BL6 WT 
male mice, fed a HFD for 20 weeks, developed alterations in weight gain and lipid 
metabolism, paralleled with impaired glucose tolerance and insulin resistance, confirming 
that we successfully set a mouse model of metabolic disorders.  
Once characterized the model, we investigated the impact of PCSK9 deficiency in both 
conditions (HFD and SFD). As extensively reported in literature [248], PCSK9 KO mice 
showed a significant reduction in cholesterol plasma levels compared to WT littermates, 
ascribable to an increased clearance of circulating LDL-C. However, effects of PCSK9 
beyond the LDLR regulation have been proposed [4]. PCSK9 targets not only the LDLR but 
also the closest family member VLDLR, which is highly expressed in adipose tissue. PCSK9 
deficient mice fed a western type diet presented augmented VAT accumulation 
associated with increased VLDLR expression, a phenotype reverted following the injection 
of a liver selective PCSK9 transgene [119]. We extended this observation by 
demonstrating that PCSK9 KO mice presented a significantly increased ectopic fat 
accumulation compared to WT mice,  both in a physiological condition (SFD) and in a 
state of metabolic dysfunction (HFD). This observation raises the question of a possible 
role of PCSK9 in modulating lipids delivery and accumulation in peripheral tissues. 
However, the main focus of this PhD project regards the role of PCSK9 in glucose 
metabolism. In spite of similar plasma glucose levels at baseline, depending on an 
overnight fasting, PCSK9 KO mice showed a significant delay in glucose clearance 
following intraperitoneal glucose injection (GTT), with both SFD and HFD. The fasting and 
refeeding experiment, performed to point out possible differences in plasma glucose 
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levels also under physiological conditions, confirmed the impaired glucose tolerance 
observed under a PCSK9 deficient state. GLP-1, secreted from L-cells of the 
gastrointestinal mucosa in response to a meal, is known to be an important blood 
glucose-lowering agent [251]. However, the intraperitoneal (IPGTT) instead of the oral 
(OGTT) administration of glucose allowed us to bypass the contribution of GLP-1 on 
glucose homeostasis, which could interfere during the fasting and refeeding experiment. 
Interestingly, the altered phenotype described in PCSK9 KO animals, independently of the 
type of diet used, was not the consequence of an impaired insulin tolerance. Indeed, the 
glycemic curves resulting from the intraperitonel injection of insulin (ITT) were 
superimposable between the two experimental groups, thus excluding the presence of an 
insulin resistant state under PCSK9 deficiency. To further extend this finding, we 
measured the ratio between phosphorylated Akt and total Akt, as an index of 
downstream activation of the insulin receptor [252], both in the liver and in the soleus 
muscle. In these tissues pAkt/Akt ratio was similar in WT and PCSK9 KO mice, confirming 
that the absence of PCSK9 do not affect the activation of the insulin pathway.  
Once excluded an insulin resistance state, we focused on pancreas and β‐cells function to 
understand the causes on which depends the impaired glucose tolerance observed in 
PCSK9 KO mice. Plasma insulin and C-peptide levels were significantly decreased in PCSK9 
KO mice compared to WT littermates, suggesting that PCSK9 deficiency might impair 
insulin secretion. As a further confirmation, plasma insulin levels increased to lower 
extent in the absence of PCSK9 also following both an IPGTT and a fast and refeeding 
experiment. On the contrary, pancreatic insulin content was significantly increased in 
PCSK9 KO mice compared to WT controls. These findings, paralleled with the altered 
pancreatic morphology described in PCSK9 KO animals, led us to hypothesize that PCSK9 
could play a central role in β‐cells function and to further investigate the molecular 
mechanisms involved.    
The LDLR, which is the main PCSK9 target, is abundantly expressed on the surface of 
pancreatic β cells, where it plays a key role in the uptake of LDL-C [2, 157]. The PCSK9-
mediated LDLR degradation has been extensively characterized in liver, while its role in 
pancreas is still debate. Firstly we considered the possibility that PCSK9 could modulate 
the expression of the LDLR also in the pancreas. Interestingly, cytofluorimetric analysis 
showed a clearly increase of the LDLR expression in islets from PCSK9 KO mice compared 
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to islets isolated from WT littermates. Recent studies have focused on the potential 
relationship between cholesterol homeostasis and insulin secretion in β-cells, with a 
deleterious effect of high intracellular cholesterol content on GSIS [245]. Mice with a 
selective inactivation of ABCA1 in β-cells, despite normal plasma cholesterol levels, 
showed an elevated total cholesterol content in islets due to an impaired cholesterol 
efflux, causing an impaired glucose tolerance [253]. Hence, considering the increased 
LDLR expression observed in PCSK9 KO mice, we assessed whether PCSK9 deficiency could 
alter cholesterol content in islets. Lipidomic analysis revealed a higher cholesterol esters 
content in PCSK9 KO islets compared to WT ones, together with significant changes in 
fatty acid lipidome. As excess cellular cholesterol is usually stored as cholesteryl esters 
[254], these findings were paralleled by a strong increase in the expression of ACAT1, a 
key enzyme in the cholesterol esterification pathway. Moreover, the impaired lipid profile 
observed in PCSK9 KO islets associated with a downregulation of genes involved in 
cholesterol biosynthesis and uptake, including HMGCoA-R and LDLR, and with a modest 
but not significant increase in genes involved in cholesterol efflux. These data showed an 
altered β-cells lipid  metabolism in the absence of PCSK9, which could determine an 
impairment in β-cells function and in turn explain the impaired glucose tolerance and the 
reduced insulin secretion observed in PCSK9 KO mice.  
To demonstrate that the PCSK9/LDLR axis and not the other known targets of PCSK9, such 
as VLDLR, ApoER2 or CD36 [118, 119, 255], is responsible for the findings observed, we 
also investigated glucose metabolism in PCSK9/LDLR DKO mice. Glucose tolerance, insulin 
tolerance and plasma insulin levels in DKO animals were similar to those of control group, 
as well as islets morphology and pancreatic insulin content. The lack of differences 
between LDLR KO and PCSK9/LDLR DKO mice confirmed the key role of the LDLR in 
driving PCSK9 dependent pancreatic dysfunction.  
Taken together these observations are critical, especially given that anti-PCSK9 therapies 
have been recently approved for the treatment of familial hypercholesterolemia and 
patients at very high cardiovascular risk. It is possible that, while on the one hand anti-
PCSK9 therapies reduce LDL-C levels and related mortality, on the other hand increase the 
risk of diabetes. Data available from one year of therapy with anti-PCSK9 agents do not 
appear to increase the risk of diabetes [256], even though the possibility that this effect 
might appear after longer term treatments could not be ruled out. 
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However, our data in tissue selective PCSK9 KO mice suggested an alternative 
explanation. Despite PCSK9 is mainly produced and released by the liver, it is also 
synthesized to a relevant amount in other tissues, including the pancreas [1]. A liver 
selective PCSK9 KO model allowed us to investigate if the phenotype observed in PSCK9 
KO (full body) mice depends on circulating liver-derived PCSK9 or on PCSK9 produced at 
the pancreatic level. Liver selective PCSK9 KO mice presented PCSK9 plasma levels below 
the detection limit, while maintaining PCSK9 production in other tissues, including 
pancreatic islets. This setting closely mimics the conditions of patients treated with anti-
PCSK9 antibodies where PCSK9 is absent in the circulation but still produced in 
extrahepatic tissues, in contrast to the genetic studies with PCSK9 LOF where all tissues 
present a PCSK9 deficient condition. Liver selective PCSK9 KO animals showed plasma and 
pancreatic insulin levels, LDLR expression, islets cholesterol esters content similar to 
those of control mice, as well as glucose tolerance and insulin tolerance. These data 
indicate that circulating PCSK9 is not affecting LDLR in pancreas and suggest the 
possibility that anti-PCSK9 therapies might have a limited impact on inducing LDLR 
expression in pancreas. 
 
In summary, we demonstrated the crucial role of PCSK9 in glucose metabolism and 
identified the biological mechanisms involved. PCSK9 critically controls the expression of 
the LDLR also at the pancreatic level and contributes to maintain a proper cholesterol 
content in β-cells.  PCSK9 deficiency results in increased LDLR expression and cholesterol 
esters accumulation in pancreatic islets, which is known to be detrimental for cellular 
functionality. Indeed, cholesterol excess impairs insulin secretion, which could explain the 
impaired glucose tolerance observed in our model. Moreover, our data indicate that this 
effect is independent of circulating PCSK9, suggesting the possibility that anti-PCSK9 
antibodies or liver specific therapies, such as siRNAs, might have a limited impact on LDLR 
expression in pancreas and beta cells function. Future studies should aim at addressing, in 
humans, the safety of targeting circulating PCSK9 on pancreatic β-cell function. 
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Impact of Pcsk9 deficiency on beta cells function 
PCSK9 produced and released from delta cells controls LDLR expression in beta cells. PCSK9 
deficiency results in increased expression of the LDLR in beta cells, thus leading to increased 
accumulation of cholesterol esters which impacts glucose-stimulated insulin secretion, resulting in 
hyperglycemia and impaired glucose tolerance observed in PCSK9 KO mice. 
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